<?xml version="1.0" encoding="UTF-8"?>
<drug type="small molecule" created="2007-10-21" updated="2020-01-02">
  <drugbank-id primary="true">DB05154</drugbank-id>
  <name>Pretomanid</name>
  <description>Persistent forms of tuberculosis (TB) have proven to be a major cause of global morbidity and mortality and a cause for significant concern. Research in recent years has been geared toward the development of novel therapies that target persistent forms of this disease, which have shown resistance to standard therapy regimens.[A182915] Pretomanid is an antimycobacterial agent that is administered with [Bedaquiline] and [Linezolid] to treat resistant forms of pulmonary TB. It was the first TB drug developed by a nonprofit organization, known as TB Alliance, and was granted FDA approval on August 14, 2019.[L8048,L8066] Unlike other therapeutic regimens for the treatment of resistant TB, which may take 18 months or longer and may not be effective, the pretomanid-containing regimen allows for a more efficacious and shorter duration of treatment with fewer drugs.[L8066]</description>
  <cas-number>187235-37-6</cas-number>
  <unii>2XOI31YC4N</unii>
  <average-mass>359.2574</average-mass>
  <monoisotopic-mass>359.072905124</monoisotopic-mass>
  <state>solid</state>
  <groups>
    <group>approved</group>
  </groups>
  <general-references>
    <articles>
      <article>
        <ref-id>A182885</ref-id>
        <pubmed-id>30833432</pubmed-id>
        <citation>Xu J, Li SY, Almeida DV, Tasneen R, Barnes-Boyle K, Converse PJ, Upton AM, Mdluli K, Fotouhi N, Nuermberger EL: Contribution of Pretomanid to Novel Regimens Containing Bedaquiline with either Linezolid or Moxifloxacin and Pyrazinamide in Murine Models of Tuberculosis. Antimicrob Agents Chemother. 2019 Apr 25;63(5). pii: AAC.00021-19. doi: 10.1128/AAC.00021-19. Print 2019 May.</citation>
      </article>
      <article>
        <ref-id>A182888</ref-id>
        <pubmed-id>29661865</pubmed-id>
        <citation>Lyons MA: Modeling and Simulation of Pretomanid Pharmacokinetics in Pulmonary Tuberculosis Patients. Antimicrob Agents Chemother. 2018 Jun 26;62(7). pii: AAC.02359-17. doi: 10.1128/AAC.02359-17. Print 2018 Jul.</citation>
      </article>
      <article>
        <ref-id>A182894</ref-id>
        <pubmed-id>29572459</pubmed-id>
        <citation>Baptista R, Fazakerley DM, Beckmann M, Baillie L, Mur LAJ: Untargeted metabolomics reveals a new mode of action of pretomanid (PA-824). Sci Rep. 2018 Mar 23;8(1):5084. doi: 10.1038/s41598-018-23110-1.</citation>
      </article>
      <article>
        <ref-id>A182897</ref-id>
        <pubmed-id>29259747</pubmed-id>
        <citation>Thompson AM, Bonnet M, Lee HH, Franzblau SG, Wan B, Wong GS, Cooper CB, Denny WA: Antitubercular Nitroimidazoles Revisited: Synthesis and Activity of the Authentic 3-Nitro Isomer of Pretomanid. ACS Med Chem Lett. 2017 Nov 13;8(12):1275-1280. doi: 10.1021/acsmedchemlett.7b00356. eCollection 2017 Dec 14.</citation>
      </article>
      <article>
        <ref-id>A182903</ref-id>
        <pubmed-id>19641733</pubmed-id>
        <citation>Manjunatha U, Boshoff HI, Barry CE: The mechanism of action of PA-824: Novel insights from transcriptional profiling. Commun Integr Biol. 2009 May;2(3):215-8. doi: 10.4161/cib.2.3.7926.</citation>
      </article>
      <article>
        <ref-id>A182915</ref-id>
        <pubmed-id>18079742</pubmed-id>
        <citation>Sacchettini JC, Rubin EJ, Freundlich JS: Drugs versus bugs: in pursuit of the persistent predator Mycobacterium tuberculosis. Nat Rev Microbiol. 2008 Jan;6(1):41-52. doi: 10.1038/nrmicro1816.</citation>
      </article>
      <article>
        <ref-id>A182972</ref-id>
        <pubmed-id>29187395</pubmed-id>
        <citation>Cano-Muniz S, Anthony R, Niemann S, Alffenaar JC: New Approaches and Therapeutic Options for Mycobacterium tuberculosis in a Dormant State. Clin Microbiol Rev. 2017 Nov 29;31(1). pii: 31/1/e00060-17. doi: 10.1128/CMR.00060-17. Print 2018 Jan.</citation>
      </article>
      <article>
        <ref-id>A182939</ref-id>
        <pubmed-id>28584788</pubmed-id>
        <citation>Kwon YS: Clinical Implications of New Drugs and Regimens for the Treatment of Drug-resistant Tuberculosis. Chonnam Med J. 2017 May;53(2):103-109. doi: 10.4068/cmj.2017.53.2.103. Epub 2017 May 25.</citation>
      </article>
      <article>
        <ref-id>A183041</ref-id>
        <pubmed-id>31254295</pubmed-id>
        <citation>Bahuguna A, Rawat DS: An overview of new antitubercular drugs, drug candidates, and their targets. Med Res Rev. 2019 Jun 28. doi: 10.1002/med.21602.</citation>
      </article>
    </articles>
    <textbooks/>
    <links>
      <link>
        <ref-id>L8048</ref-id>
        <title>Pretomanid FDA label, August 2019</title>
        <url>https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212862s000lbl.pdf</url>
      </link>
      <link>
        <ref-id>L8051</ref-id>
        <title>MSDS, Pretomanid</title>
        <url>https://www.sigmaaldrich.com/catalog/product/sigma/sml1290?lang=en&amp;region=US</url>
      </link>
      <link>
        <ref-id>L8057</ref-id>
        <title>Pretomanid briefing document, FDA</title>
        <url>https://www.fda.gov/media/127592/download</url>
      </link>
      <link>
        <ref-id>L8066</ref-id>
        <title>TB Alliance</title>
        <url>https://www.tballiance.org/news/fda-approves-new-treatment-highly-drug-resistant-forms-tuberculosis</url>
      </link>
      <link>
        <ref-id>L8069</ref-id>
        <title>TB Alliance presentation slides</title>
        <url>https://www.fda.gov/media/128001/download</url>
      </link>
    </links>
    <attachments/>
  </general-references>
  <synthesis-reference>Thompson AM, Bonnet M, Lee HH, et al. Antitubercular Nitroimidazoles Revisited: Synthesis and Activity of the Authentic 3-Nitro Isomer of Pretomanid. ACS Med Chem Lett. 2017;8(12):1275â€“1280. Published 2017 Nov 13. doi:10.1021/acsmedchemlett.7b00356</synthesis-reference>
  <indication>Pretomanid is indicated for adults in combination with bedaquiline and linezolid for the treatment of pulmonary forms of nonresponsive multidrug-resistant (MDR), extensively drug-resistant (XDR), and treatment-intolerant forms of pulmonary tuberculosis (TB).[L8048]&#13;
&#13;
It is important to note that the following conditions are not approved indications for pretomanid therapy, according to the FDA[L8048]:&#13;
&#13;
Drug-sensitive (DS) tuberculosis, latent tuberculosis caused by M.tuberculosis, extra-pulmonary tuberculosis caused by M.tuberculosis, and &#13;
multidrug-resistant TB that is not treatment-intolerant or nonresponsive to conventional TB therapy.</indication>
  <pharmacodynamics>Pretomanid kills the actively replicating bacteria causing tuberculosis, known as Mycobacterium tuberculosis, and shortens the duration of treatment in patients who suffer from resistant forms of pulmonary TB by killing dormant bacteria.[A182897,A182903,A182972,L8048]&#13;
&#13;
In rodent models of tuberculosis infection, pretomanid administered in a regimen with bedaquiline and linezolid caused a significant reduction in pulmonary bacterial cell counts. A decrease in the frequency of TB relapses at 2 and 3 months after treatment was observed after the administration of this regimen, when compared to the administration of a 2-drug regimen.[L8048] Successful outcomes have been recorded for patients with XDR and MDR following a clinical trial of the pretomanid regimen, demonstrating a 90% cure rate after 6 months.[L8069]&#13;
&#13;
**A note on cardiac QT prolongation, hepatotoxicity, and myelosuppression**&#13;
&#13;
This drug has the propensity to caused cardiac QT interval prolongation and significant hepatotoxicity, as well as myelosuppression. Caution must be observed during the administration of this drug.[L8048,L8057]</pharmacodynamics>
  <mechanism-of-action>Pretomanid is a prodrug which is metabolically activated by a nitroreductase enzyme, known as Ddn, producing various active metabolites that are responsible for its other therapeutic actions, particularly the induction of nitric oxide. The nitroreductase enzyme which activates pretomanid is deazaflavin dependent and relies on reduced cofactor F420. Reduction of F420 occurs via the enzyme glucose-6-phosphate dehydrogenase.[L8048] Reduction of pretomanid's imidazole ring at the C-3 position causes the formation of the metabolites, which include a des-nitro derivative. The formation of this derivative leads to increased levels of nitric oxide, leading to bactericidal activities under anaerobic conditions via its action as a bacterial respiratory poison.[A182894,L8048] Bactericidal activity against anaerobes is reported to be associated with a shortened duration of antibiotic treatment.[A182897] &#13;
&#13;
Pretomanid exerts aerobic bactericidal effects through its inhibitory actions on bacterial cell wall mycolic acid biosynthesis. This allows for the killing of actively replicating Mycobacterium tuberculosis bacteria, resulting in the treatment of active tuberculosis infection.[A182897,L8048] The molecular mechanism of the above bactericidal effects is poorly understood at this time, but may involve effects exerted on various genes that affect the cell wall, including the fasI and fasII as well as the efpA and iniBAC operons. Other possible targets include the genes of the cyd operon. The clinical effects of the above target relations are unknown at this time.[A182903] </mechanism-of-action>
  <toxicity>To this date, there is no documented experience with the treatment of a pretomanid overdose. The FDA label advises that general supportive measures are taken to manage an overdose, such as monitoring vital signs in addition to performing ECG testing for a prolonged QT interval in the case of an overdose.[L8048]</toxicity>
  <metabolism>Various reductive and oxidative pathways are responsible for pretomanid metabolism, with no single major metabolic pathway identified. According to in vitro studies, CYP3A4 is responsible for a 20% contribution to the metabolism of pretomanid.[L8048]</metabolism>
  <absorption>This drug is absorbed in the gastrointestinal tract. The steady-state Cmax of pretomanid was estimated to be 1.7 Î¼g/mL after a single 200mg oral dose.[L8048] In a separate pharmacokinetic modeling study, the Cmax of a 200mg dose was 1.1 Î¼g/ml.[A182888] Tmax in a study of healthy subjects in the fed or unfed state was achieved within 4 to 5 hours.[L8048] The AUC in the same study was found to be about 28.1 Î¼gâ€¢hr/mL in the fasted state and about 51.6 Î¼gâ€¢hr/mL in the fed state, showing higher absorption when taken with high-calorie and high-fat food.[L8048]</absorption>
  <half-life>The elimination half-life was determined to be 16.9-17.4 hours in a pharmacokinetic study of healthy subjects.[L8048] An FDA briefing document reports a half-life of 18 hours.[L8057]</half-life>
  <protein-binding>The plasma protein binding of pretomanid is about 86.4%.[L8048]</protein-binding>
  <route-of-elimination>Healthy adult male volunteers were administered a 1,100 mg oral dose of radiolabeled pretomanid in one pharmacokinetic study. An average of about 53% of the radioactive dose was found to be excreted in the urine. Approximately 38% was measured mainly as metabolites in the feces. A estimated 1% of the radiolabeled dose was measured as unchanged drug in the urine.[L8048]</route-of-elimination>
  <volume-of-distribution>A pharmacokinetic modeling study estimated the volume of distribution at 130 Â± 5L.[A182888] A pharmacokinetic study in healthy volunteers determined a volume of distribution of about 180 Â± 51.3L in fasted state and 97.0 Â± 17.2L in the fed state.[L8048]</volume-of-distribution>
  <clearance>The clearance of pretomanid in a pharmacokinetic simulation study has been estimated at 4.8 Â± 0.2 liters/h.[A182888]&#13;
According to the FDA label, the clearance of a single 200 mg oral dose of pretomanid is estimated to be 7.6 liters/h in the fasted state, and 3.9 liters/h in the fed state.[L8048]</clearance>
  <classification>
    <description>This compound belongs to the class of organic compounds known as benzylethers. These are aromatic ethers with the general formula ROCR' (R = alkyl, aryl; R'=benzene).</description>
    <direct-parent>Benzylethers</direct-parent>
    <kingdom>Organic compounds</kingdom>
    <superclass>Benzenoids</superclass>
    <class>Benzene and substituted derivatives</class>
    <subclass>Benzylethers</subclass>
    <alternative-parent>Alkyl aryl ethers</alternative-parent>
    <alternative-parent>Alkyl fluorides</alternative-parent>
    <alternative-parent>Azacyclic compounds</alternative-parent>
    <alternative-parent>Dialkyl ethers</alternative-parent>
    <alternative-parent>Heteroaromatic compounds</alternative-parent>
    <alternative-parent>Hydrocarbon derivatives</alternative-parent>
    <alternative-parent>Imidolactams</alternative-parent>
    <alternative-parent>N-substituted imidazoles</alternative-parent>
    <alternative-parent>Nitroaromatic compounds</alternative-parent>
    <alternative-parent>Nitroimidazoles</alternative-parent>
    <alternative-parent>Organic oxides</alternative-parent>
    <alternative-parent>Organic oxoazanium compounds</alternative-parent>
    <alternative-parent>Organofluorides</alternative-parent>
    <alternative-parent>Organonitrogen compounds</alternative-parent>
    <alternative-parent>Organopnictogen compounds</alternative-parent>
    <alternative-parent>Oxacyclic compounds</alternative-parent>
    <alternative-parent>Phenol ethers</alternative-parent>
    <alternative-parent>Phenoxy compounds</alternative-parent>
    <alternative-parent>Propargyl-type 1,3-dipolar organic compounds</alternative-parent>
    <alternative-parent>Trihalomethanes</alternative-parent>
    <substituent>Alkyl aryl ether</substituent>
    <substituent>Alkyl fluoride</substituent>
    <substituent>Alkyl halide</substituent>
    <substituent>Allyl-type 1,3-dipolar organic compound</substituent>
    <substituent>Aromatic heteropolycyclic compound</substituent>
    <substituent>Azacycle</substituent>
    <substituent>Azole</substituent>
    <substituent>Benzylether</substituent>
    <substituent>C-nitro compound</substituent>
    <substituent>Dialkyl ether</substituent>
    <substituent>Ether</substituent>
    <substituent>Halomethane</substituent>
    <substituent>Heteroaromatic compound</substituent>
    <substituent>Hydrocarbon derivative</substituent>
    <substituent>Imidazole</substituent>
    <substituent>Imidolactam</substituent>
    <substituent>N-substituted imidazole</substituent>
    <substituent>Nitroaromatic compound</substituent>
    <substituent>Nitroimidazole</substituent>
    <substituent>Organic 1,3-dipolar compound</substituent>
    <substituent>Organic nitro compound</substituent>
    <substituent>Organic nitrogen compound</substituent>
    <substituent>Organic oxide</substituent>
    <substituent>Organic oxoazanium</substituent>
    <substituent>Organic oxygen compound</substituent>
    <substituent>Organofluoride</substituent>
    <substituent>Organohalogen compound</substituent>
    <substituent>Organoheterocyclic compound</substituent>
    <substituent>Organonitrogen compound</substituent>
    <substituent>Organooxygen compound</substituent>
    <substituent>Organopnictogen compound</substituent>
    <substituent>Oxacycle</substituent>
    <substituent>Phenol ether</substituent>
    <substituent>Phenoxy compound</substituent>
    <substituent>Propargyl-type 1,3-dipolar organic compound</substituent>
    <substituent>Trihalomethane</substituent>
  </classification>
  <salts/>
  <synonyms>
    <synonym language="english" coder="inn/usan">Pretomanid</synonym>
  </synonyms>
  <products>
    <product>
      <name>Pretomanid</name>
      <labeller>Mylan Specialty L.P.</labeller>
      <ndc-id/>
      <ndc-product-code>49502-476</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-11-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>200 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA212862</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
  </products>
  <international-brands/>
  <mixtures>
    <mixture>
      <name>Pretomanid</name>
      <ingredients>Pretomanid</ingredients>
    </mixture>
  </mixtures>
  <packagers/>
  <manufacturers/>
  <prices/>
  <categories>
    <category>
      <category>Antituberculosis Agents</category>
      <mesh-id>D000995</mesh-id>
    </category>
    <category>
      <category>Cytochrome P-450 CYP3A Substrates</category>
      <mesh-id/>
    </category>
    <category>
      <category>Cytochrome P-450 CYP3A4 Substrates</category>
      <mesh-id/>
    </category>
    <category>
      <category>Cytochrome P-450 CYP3A4 Substrates (strength unknown)</category>
      <mesh-id/>
    </category>
    <category>
      <category>Cytochrome P-450 Substrates</category>
      <mesh-id/>
    </category>
    <category>
      <category>Imidazoles</category>
      <mesh-id>D007093</mesh-id>
    </category>
    <category>
      <category>Nitro Compounds</category>
      <mesh-id>D009574</mesh-id>
    </category>
    <category>
      <category>OAT3/SLC22A8 Inhibitors</category>
      <mesh-id/>
    </category>
  </categories>
  <affected-organisms>
    <affected-organism>Mycobacterium tuberculosis</affected-organism>
  </affected-organisms>
  <dosages>
    <dosage>
      <form>Tablet</form>
      <route>Oral</route>
      <strength>200 mg/1</strength>
    </dosage>
  </dosages>
  <atc-codes/>
  <ahfs-codes/>
  <pdb-entries/>
  <patents/>
  <food-interactions/>
  <drug-interactions>
    <drug-interaction>
      <drugbank-id>DB00176</drugbank-id>
      <name>Fluvoxamine</name>
      <description>The serum concentration of Pretomanid can be increased when it is combined with Fluvoxamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00196</drugbank-id>
      <name>Fluconazole</name>
      <description>The serum concentration of Pretomanid can be increased when it is combined with Fluconazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00199</drugbank-id>
      <name>Erythromycin</name>
      <description>The serum concentration of Pretomanid can be increased when it is combined with Erythromycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00227</drugbank-id>
      <name>Lovastatin</name>
      <description>The serum concentration of Pretomanid can be increased when it is combined with Lovastatin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00246</drugbank-id>
      <name>Ziprasidone</name>
      <description>The serum concentration of Pretomanid can be increased when it is combined with Ziprasidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00270</drugbank-id>
      <name>Isradipine</name>
      <description>The serum concentration of Pretomanid can be increased when it is combined with Isradipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00343</drugbank-id>
      <name>Diltiazem</name>
      <description>The serum concentration of Pretomanid can be increased when it is combined with Diltiazem.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00363</drugbank-id>
      <name>Clozapine</name>
      <description>The serum concentration of Pretomanid can be increased when it is combined with Clozapine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00502</drugbank-id>
      <name>Haloperidol</name>
      <description>The serum concentration of Pretomanid can be increased when it is combined with Haloperidol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00582</drugbank-id>
      <name>Voriconazole</name>
      <description>The serum concentration of Pretomanid can be increased when it is combined with Voriconazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00622</drugbank-id>
      <name>Nicardipine</name>
      <description>The serum concentration of Pretomanid can be increased when it is combined with Nicardipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00661</drugbank-id>
      <name>Verapamil</name>
      <description>The serum concentration of Pretomanid can be increased when it is combined with Verapamil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00673</drugbank-id>
      <name>Aprepitant</name>
      <description>The serum concentration of Pretomanid can be increased when it is combined with Aprepitant.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00951</drugbank-id>
      <name>Isoniazid</name>
      <description>The serum concentration of Pretomanid can be increased when it is combined with Isoniazid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01007</drugbank-id>
      <name>Tioconazole</name>
      <description>The serum concentration of Pretomanid can be increased when it is combined with Tioconazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01087</drugbank-id>
      <name>Primaquine</name>
      <description>The serum concentration of Pretomanid can be increased when it is combined with Primaquine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01110</drugbank-id>
      <name>Miconazole</name>
      <description>The serum concentration of Pretomanid can be increased when it is combined with Miconazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01406</drugbank-id>
      <name>Danazol</name>
      <description>The serum concentration of Pretomanid can be increased when it is combined with Danazol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02703</drugbank-id>
      <name>Fusidic acid</name>
      <description>The serum concentration of Pretomanid can be increased when it is combined with Fusidic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04832</drugbank-id>
      <name>Zimelidine</name>
      <description>The serum concentration of Pretomanid can be increased when it is combined with Zimelidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04855</drugbank-id>
      <name>Dronedarone</name>
      <description>The serum concentration of Pretomanid can be increased when it is combined with Dronedarone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04896</drugbank-id>
      <name>Milnacipran</name>
      <description>The serum concentration of Pretomanid can be increased when it is combined with Milnacipran.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06290</drugbank-id>
      <name>Simeprevir</name>
      <description>The serum concentration of Pretomanid can be increased when it is combined with Simeprevir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06636</drugbank-id>
      <name>Isavuconazonium</name>
      <description>The serum concentration of Pretomanid can be increased when it is combined with Isavuconazonium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06700</drugbank-id>
      <name>Desvenlafaxine</name>
      <description>The serum concentration of Pretomanid can be increased when it is combined with Desvenlafaxine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06712</drugbank-id>
      <name>Nilvadipine</name>
      <description>The serum concentration of Pretomanid can be increased when it is combined with Nilvadipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06731</drugbank-id>
      <name>Seproxetine</name>
      <description>The serum concentration of Pretomanid can be increased when it is combined with Seproxetine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08865</drugbank-id>
      <name>Crizotinib</name>
      <description>The serum concentration of Pretomanid can be increased when it is combined with Crizotinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08882</drugbank-id>
      <name>Linagliptin</name>
      <description>The serum concentration of Pretomanid can be increased when it is combined with Linagliptin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08933</drugbank-id>
      <name>Luliconazole</name>
      <description>The serum concentration of Pretomanid can be increased when it is combined with Luliconazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08953</drugbank-id>
      <name>Indalpine</name>
      <description>The serum concentration of Pretomanid can be increased when it is combined with Indalpine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09048</drugbank-id>
      <name>Netupitant</name>
      <description>The serum concentration of Pretomanid can be increased when it is combined with Netupitant.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09227</drugbank-id>
      <name>Barnidipine</name>
      <description>The serum concentration of Pretomanid can be increased when it is combined with Barnidipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09231</drugbank-id>
      <name>Benidipine</name>
      <description>The serum concentration of Pretomanid can be increased when it is combined with Benidipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11581</drugbank-id>
      <name>Venetoclax</name>
      <description>The serum concentration of Pretomanid can be increased when it is combined with Venetoclax.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11633</drugbank-id>
      <name>Isavuconazole</name>
      <description>The serum concentration of Pretomanid can be increased when it is combined with Isavuconazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14019</drugbank-id>
      <name>Fosnetupitant</name>
      <description>The serum concentration of Pretomanid can be increased when it is combined with Fosnetupitant.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00091</drugbank-id>
      <name>Cyclosporine</name>
      <description>The serum concentration of Pretomanid can be increased when it is combined with Cyclosporine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00537</drugbank-id>
      <name>Ciprofloxacin</name>
      <description>The serum concentration of Pretomanid can be increased when it is combined with Ciprofloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00342</drugbank-id>
      <name>Terfenadine</name>
      <description>The serum concentration of Pretomanid can be increased when it is combined with Terfenadine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00503</drugbank-id>
      <name>Ritonavir</name>
      <description>The serum concentration of Pretomanid can be increased when it is combined with Ritonavir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00625</drugbank-id>
      <name>Efavirenz</name>
      <description>The serum concentration of Pretomanid can be increased when it is combined with Efavirenz.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00696</drugbank-id>
      <name>Ergotamine</name>
      <description>The serum concentration of Pretomanid can be increased when it is combined with Ergotamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00705</drugbank-id>
      <name>Delavirdine</name>
      <description>The serum concentration of Pretomanid can be increased when it is combined with Delavirdine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00836</drugbank-id>
      <name>Loperamide</name>
      <description>The serum concentration of Pretomanid can be increased when it is combined with Loperamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00872</drugbank-id>
      <name>Conivaptan</name>
      <description>The serum concentration of Pretomanid can be increased when it is combined with Conivaptan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00932</drugbank-id>
      <name>Tipranavir</name>
      <description>The serum concentration of Pretomanid can be increased when it is combined with Tipranavir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00976</drugbank-id>
      <name>Telithromycin</name>
      <description>The serum concentration of Pretomanid can be increased when it is combined with Telithromycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01026</drugbank-id>
      <name>Ketoconazole</name>
      <description>The serum concentration of Pretomanid can be increased when it is combined with Ketoconazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01072</drugbank-id>
      <name>Atazanavir</name>
      <description>The serum concentration of Pretomanid can be increased when it is combined with Atazanavir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01127</drugbank-id>
      <name>Econazole</name>
      <description>The serum concentration of Pretomanid can be increased when it is combined with Econazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01149</drugbank-id>
      <name>Nefazodone</name>
      <description>The serum concentration of Pretomanid can be increased when it is combined with Nefazodone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01167</drugbank-id>
      <name>Itraconazole</name>
      <description>The serum concentration of Pretomanid can be increased when it is combined with Itraconazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01183</drugbank-id>
      <name>Naloxone</name>
      <description>The serum concentration of Pretomanid can be increased when it is combined with Naloxone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01211</drugbank-id>
      <name>Clarithromycin</name>
      <description>The serum concentration of Pretomanid can be increased when it is combined with Clarithromycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01232</drugbank-id>
      <name>Saquinavir</name>
      <description>The serum concentration of Pretomanid can be increased when it is combined with Saquinavir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01263</drugbank-id>
      <name>Posaconazole</name>
      <description>The serum concentration of Pretomanid can be increased when it is combined with Posaconazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01264</drugbank-id>
      <name>Darunavir</name>
      <description>The serum concentration of Pretomanid can be increased when it is combined with Darunavir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01601</drugbank-id>
      <name>Lopinavir</name>
      <description>The serum concentration of Pretomanid can be increased when it is combined with Lopinavir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02520</drugbank-id>
      <name>Ditiocarb</name>
      <description>The serum concentration of Pretomanid can be increased when it is combined with Ditiocarb.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04868</drugbank-id>
      <name>Nilotinib</name>
      <description>The serum concentration of Pretomanid can be increased when it is combined with Nilotinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05521</drugbank-id>
      <name>Telaprevir</name>
      <description>The serum concentration of Pretomanid can be increased when it is combined with Telaprevir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06595</drugbank-id>
      <name>Midostaurin</name>
      <description>The serum concentration of Pretomanid can be increased when it is combined with Midostaurin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09054</drugbank-id>
      <name>Idelalisib</name>
      <description>The serum concentration of Pretomanid can be increased when it is combined with Idelalisib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09065</drugbank-id>
      <name>Cobicistat</name>
      <description>The serum concentration of Pretomanid can be increased when it is combined with Cobicistat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09101</drugbank-id>
      <name>Elvitegravir</name>
      <description>The serum concentration of Pretomanid can be increased when it is combined with Elvitegravir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09118</drugbank-id>
      <name>Stiripentol</name>
      <description>The serum concentration of Pretomanid can be increased when it is combined with Stiripentol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11672</drugbank-id>
      <name>Curcumin</name>
      <description>The serum concentration of Pretomanid can be increased when it is combined with Curcumin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11730</drugbank-id>
      <name>Ribociclib</name>
      <description>The serum concentration of Pretomanid can be increased when it is combined with Ribociclib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11779</drugbank-id>
      <name>Danoprevir</name>
      <description>The serum concentration of Pretomanid can be increased when it is combined with Danoprevir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13179</drugbank-id>
      <name>Troleandomycin</name>
      <description>The serum concentration of Pretomanid can be increased when it is combined with Troleandomycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00763</drugbank-id>
      <name>Methimazole</name>
      <description>The serum concentration of Pretomanid can be increased when it is combined with Methimazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08873</drugbank-id>
      <name>Boceprevir</name>
      <description>The serum concentration of Pretomanid can be increased when it is combined with Boceprevir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09046</drugbank-id>
      <name>Metreleptin</name>
      <description>The metabolism of Pretomanid can be increased when combined with Metreleptin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06119</drugbank-id>
      <name>Cenobamate</name>
      <description>The serum concentration of Pretomanid can be decreased when it is combined with Cenobamate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11642</drugbank-id>
      <name>Pitolisant</name>
      <description>The serum concentration of Pretomanid can be decreased when it is combined with Pitolisant.</description>
    </drug-interaction>
  </drug-interactions>
  <calculated-properties>
    <property>
      <kind>logP</kind>
      <value>2.8</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logS</kind>
      <value>-4.5</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>Water Solubility</kind>
      <value>1.17e-02 g/l</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logP</kind>
      <value>4.14</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>IUPAC Name</kind>
      <value>(6S)-2-nitro-6-{[4-(trifluoromethoxy)phenyl]methoxy}-5H,6H,7H-imidazo[2,1-b][1,3]oxazine</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Traditional IUPAC Name</kind>
      <value>(6S)-2-nitro-6-{[4-(trifluoromethoxy)phenyl]methoxy}-5H,6H,7H-imidazo[2,1-b][1,3]oxazine</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Weight</kind>
      <value>359.2574</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Monoisotopic Weight</kind>
      <value>359.072905124</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>SMILES</kind>
      <value>[O-][N+](=O)C1=CN2C[C@@H](COC2=N1)OCC1=CC=C(OC(F)(F)F)C=C1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>C14H12F3N3O5</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChI</kind>
      <value>InChI=1S/C14H12F3N3O5/c15-14(16,17)25-10-3-1-9(2-4-10)7-23-11-5-19-6-12(20(21)22)18-13(19)24-8-11/h1-4,6,11H,5,7-8H2/t11-/m0/s1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChIKey</kind>
      <value>ZLHZLMOSPGACSZ-NSHDSACASA-N</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polar Surface Area (PSA)</kind>
      <value>91.33</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Refractivity</kind>
      <value>73.91</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polarizability</kind>
      <value>30.26</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rotatable Bond Count</kind>
      <value>6</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Acceptor Count</kind>
      <value>6</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Donor Count</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest basic)</kind>
      <value>-3</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Physiological Charge</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Number of Rings</kind>
      <value>3</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Bioavailability</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rule of Five</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Ghose Filter</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>MDDR-Like Rule</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
  </calculated-properties>
  <experimental-properties>
    <property>
      <kind>Water Solubility</kind>
      <value>&lt;1 mg/mL</value>
      <source>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4139342/</source>
    </property>
    <property>
      <kind>Boiling Point</kind>
      <value>462.3Â±55.0</value>
      <source>http://www.chemspider.com/Chemical-Structure.401693.html</source>
    </property>
    <property>
      <kind>logP</kind>
      <value>2.75</value>
      <source>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4139342/</source>
    </property>
    <property>
      <kind>caco2 Permeability</kind>
      <value>27.6</value>
      <source>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4139342/</source>
    </property>
    <property>
      <kind>pKa</kind>
      <value>7.0</value>
      <source>https://www.researchgate.net/publication/310833979_Simultaneous_HPLC_assay_for_pretomanid_PA-824_moxifloxacin_and_pyrazinamide_in_an_inhaler_formulation_for_drug-resistant_tuberculosis</source>
    </property>
  </experimental-properties>
  <external-identifiers>
    <external-identifier>
      <resource>PubChem Compound</resource>
      <identifier>456199</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Substance</resource>
      <identifier>175426953</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChemSpider</resource>
      <identifier>401693</identifier>
    </external-identifier>
    <external-identifier>
      <resource>BindingDB</resource>
      <identifier>50363237</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Pretomanid</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEMBL</resource>
      <identifier>CHEMBL227875</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links/>
  <pathways/>
  <reactions>
    <reaction>
      <sequence>1</sequence>
      <left-element>
        <drugbank-id>DB05154</drugbank-id>
        <name>Pretomanid</name>
      </left-element>
      <right-element>
        <drugbank-id>DBMET02737</drugbank-id>
        <name>Des-nitroso derivative, Pretomanid</name>
      </right-element>
      <enzymes>
        <enzyme>
          <drugbank-id>BE0009325</drugbank-id>
          <name>Deazaflavin-dependent nitroreductase</name>
          <uniprot-id>P9WP15</uniprot-id>
        </enzyme>
      </enzymes>
    </reaction>
  </reactions>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets>
    <target position="4">
      <id>BE0009744</id>
      <name>Fatty acid synthetase</name>
      <organism>Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv)</organism>
      <actions>
        <action>other/unknown</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A182903</ref-id>
            <pubmed-id>19641733</pubmed-id>
            <citation>Manjunatha U, Boshoff HI, Barry CE: The mechanism of action of PA-824: Novel insights from transcriptional profiling. Commun Integr Biol. 2009 May;2(3):215-8. doi: 10.4161/cib.2.3.7926.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P95029" source="TrEMBL">
        <name>Probable fatty acid synthase Fas (Fatty acid synthetase)</name>
        <general-function/>
        <specific-function>Enoyl-[acyl-carrier-protein] reductase (nadh) activity</specific-function>
        <gene-name>fas</gene-name>
        <locus/>
        <cellular-location/>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi/>
        <molecular-weight>326251.13</molecular-weight>
        <chromosome-location/>
        <organism ncbi-taxonomy-id="83332">Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv)</organism>
        <external-identifiers>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P95029</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>P95029_MYCTU</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms/>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0052110|Probable fatty acid synthase Fas (Fatty acid synthetase)
MTIHEHDRVSADRGGDSPHTTHALVDRLMAGEPYAVAFGGQGSAWLETLEELVSATGIET
ELATLVGEAELLLDPVTDELIVVRPIGFEPLQWVRALAAEDPVPSDKHLTSAAVSVPGVL
LTQIAATRALARQGMDLVATPPVAMAGHSQGVLAVEALKAGGARDVELFALAQLIGAAGT
LVARRRGISVLGDRPPMVSVTNADPERIGRLLDEFAQDVRTVLPPVLSIRNGRRAVVITG
TPEQLSRFELYCRQISEKEEADRKNKVRGGDVFSPVFEPVQVEVGFHTPRLSDGIDIVAG
WAEKAGLDVALARELADAILIRKVDWVDEITRVHAAGARWILDLGPGDILTRLTAPVIRG
LGIGIVPAATRGGQRNLFTVGATPEVARAWSSYAPTVVRLPDGRVKLSTKFTRLTGRSPI
LLAGMTPTTVDAKIVAAAANAGHWAELAGGGQVTEEIFGNRIEQMAGLLEPGRTYQFNAL
FLDPYLWKLQVGGKRLVQKARQSGAAIDGVVISAGIPDLDEAVELIDELGDIGISHVVFK
PGTIEQIRSVIRIATEVPTKPVIMHVEGGRAGGHHSWEDLDDLLLATYSELRSRANITVC
VGGGIGTPRRAAEYLSGRWAQAYGFPLMPIDGILVGTAAMATKESTTSPSVKRMLVDTQG
TDQWISAGKAQGGMASSRSQLGADIHEIDNSASRCGRLLDEVAGDAEAVAERRDEIIAAM
AKTAKPYFGDVADMTYLQWLRRYVELAIGEGNSTADTASVGSPWLADTWRDRFEQMLQRA
EARLHPQDFGPIQTLFTDAGLLDNPQQAIAALLARYPDAETVQLHPADVPFFVTLCKTLG
KPVNFVPVIDQDVRRWWRSDSLWQAHDARYDADAVCIIPGTASVAGITRMDEPVGELLDR
FEQAAIDEVLGAGVEPKDVASRRLGRADVAGPLAVVLDAPDVRWAGRTVTNPVHRIADPA
EWQVHDGPENPRATHSSTGARLQTHGDDVALSVPVSGTWVDIRFTLPANTVDGGTPVIAT
EDATSAMRTVLAIAAGVDSPEFLPAVANGTATLTVDWHPERVADHTGVTATFGEPLAPSL
TNVPDALVGPCWPAVFAAIGSAVTDTGEPVVEGLLSLVHLDHAARVVGQLPTVPAQLTVT
ATAANATDTDMGRVVPVSVVVTGADGAVIATLEERFAILGRTGSAELADPARAGGAVSAN
ATDTPRRRRRDVTITAPVDMRPFAVVSGDHNPIHTDRAAALLAGLESPIVHGMWLSAAAQ
HAVTATDGQARPPARLVGWTARFLGMVRPGDEVDFRVERVGIDQGAEIVDVAARVGSDLV
MSASARLAAPKTVYAFPGQGIQHKGMGMEVRARSKAARKVWDTADKFTRDTLGFSVLHVV
RDNPTSIIASGVHYHHPDGVLYLTQFTQVAMATVAAAQVAEMREQGAFVEGAIACGHSVG
EYTALACVTGIYQLEALLEMVFHRGSKMHDIVPRDELGRSNYRLAAIRPSQIDLDDADVP
AFVAGIAESTGEFLEIVNFNLRGSQYAIAGTVRGLEALEAEVERRRELTGGRRSFILVPG
IDVPFHSRVLRVGVAEFRRSLDRVMPRDADPDLIIGRYIPNLVPRLFTLDRDFIQEIRDL
VPAEPLDEILADYDTWLRERPREMARTVFIELLAWQFASPVRWIETQDLLFIEEAAGGLG
VERFVEIGVKSSPTVAGLATNTLKLPEYAHSTVEVLNAERDAAVLFATDTDPEPEPEEDE
PVAESPAPDVVSEAAPVAPAASSAGPRPDDLVFDAADATLALIALSAKMRIDQIEELDSI
ESITDGASSRRNQLLVDLGSELNLGAIDGAAESDLAGLRSQVTKLARTYKPYGPVLSDAI
NDQLRTVLGPSGKRPGAIAERVKKTWELGEGWAKHVTVEVALGTREGSSVRGGAMGHLHE
GALADAASVDKVIDAAVASVAARQGVSVALPSAGSGGGATIDAAALSEFTDQITGREGVL
ASAARLVLGQLGLDDPVNALPAAPDSELIDLVTAELGADWPRLVAPVFDPKKAVVFDDRW
ASAREDLVKLWLTDEGDIDADWPRLAERFEGAGHVVATQATWWQGKSLAAGRQIHASLYG
RIAAGAENPEPGRYGGEVAVVTGASKGSIAASVVARLLDGGATVIATTSKLDEERLAFYR
TLYRDHARYGAALWLVAANMASYSDVDALVEWIGTEQTESLGPQSIHIKDAQTPTLLFPF
AAPRVVGDLSEAGSRAEMEMKVLLWAVQRLIGGLSTIGAERDIASRLHVVLPGSPNRGMF
GGDGAYGEAKSALDAVVSRWHAESSWAARVSLAHALIGWTRGTGLMGHNDAIVAAVEEAG
VTTYSTDEMAALLLDLCDAESKVAAARSPIKADLTGGLAEANLDMAELAAKAREQMSAAA
AVDEDAEAPGAIAALPSPPRGFTPAPPPQWDDLDVDPADLVVIVGGAEIGPYGSSRTRFE
MEVENELSAAGVLELAWTTGLIRWEDDPQPGWYDTESGEMVDESELVQRYHDAVVQRVGI
REFVDDGAIDPDHASPLLVSVFLEKDFAFVVSSEADARAFVEFDPEHTVIRPVPDSTDWQ
VIRKAGTEIRVPRKTKLSRVVGGQIPTGFDPTVWGISADMAGSIDRLAVWNMVATVDAFL
SSGFSPAEVMRYVHPSLVANTQGTGMGGGTSMQTMYHGNLLGRNKPNDIFQEVLPNIIAA
HVVQSYVGSYGAMIHPVAACATAAVSVEEGVDKIRLGKAQLVVAGGLDDLTLEGIIGFGD
MAATADTSMMCGRGIHDSKFSRPNDRRRLGFVEAQGGGTILLARGDLALRMGLPVLAVVA
FAQSFGDGVHTSIPAPGLGALGAGRGGKDSPLARALAKLGVAADDVAVISKHDTSTLAND
PNETELHERLADALGRSEGAPLFVVSQKSLTGHAKGGAAVFQMMGLCQILRDGVIPPNRS
LDCVDDELAGSAHFVWVRDTLRLGGKFPLKAGMLTSLGFGHVSGLVALVHPQAFIASLDP
AQRADYQRRADARLLAGQRRLASAIAGGAPMYQRPGDRRFDHHAPERPQEASMLLNPAAR
LGDGEAYIG</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0052111|Probable fatty acid synthase Fas (Fatty acid synthetase) (fas)
GTGACGATCCACGAGCACGACCGGGTGTCCGCTGATCGCGGCGGGGACAGCCCGCATACC
ACCCACGCTCTGGTCGATCGCCTCATGGCTGGTGAGCCCTACGCTGTCGCATTCGGTGGC
CAGGGCAGCGCCTGGCTGGAAACCCTCGAAGAGCTGGTGTCGGCCACCGGGATAGAAACC
GAGTTGGCGACGTTGGTCGGTGAGGCAGAGCTGTTGCTCGATCCGGTCACCGACGAGCTG
ATTGTGGTGCGCCCGATCGGTTTCGAGCCGCTGCAATGGGTACGCGCACTGGCGGCCGAG
GACCCGGTTCCGTCCGACAAGCACCTGACGTCGGCCGCCGTGTCGGTGCCCGGCGTGTTG
CTTACCCAGATCGCGGCGACCCGGGCGCTGGCCCGTCAAGGCATGGACCTCGTGGCCACC
CCGCCGGTCGCCATGGCGGGGCATTCGCAAGGTGTGCTGGCGGTGGAAGCCCTCAAGGCT
GGTGGGGCACGCGACGTCGAGCTGTTTGCCTTGGCCCAGTTGATCGGTGCCGCCGGAACG
CTGGTGGCCCGCCGGCGCGGAATTTCCGTCCTGGGCGATCGCCCGCCGATGGTATCGGTC
ACCAACGCCGACCCCGAGCGCATCGGCCGGTTGCTCGACGAGTTCGCCCAGGACGTGCGC
ACGGTGCTGCCACCGGTGTTGTCCATCCGCAACGGCCGGCGTGCCGTCGTCATCACCGGC
ACCCCCGAGCAGCTGTCGCGTTTCGAGCTTTATTGCCGCCAGATCTCCGAGAAGGAAGAA
GCCGACCGCAAGAACAAGGTCCGCGGCGGCGACGTCTTCTCGCCGGTCTTCGAGCCGGTG
CAGGTGGAGGTGGGCTTTCACACCCCGCGGCTATCCGACGGGATCGACATCGTCGCGGGC
TGGGCCGAGAAGGCGGGCCTCGATGTCGCCTTGGCTCGGGAGCTGGCCGATGCCATCTTG
ATCAGAAAGGTCGACTGGGTCGACGAGATCACCCGTGTCCACGCGGCCGGCGCCCGCTGG
ATCCTCGACCTGGGGCCGGGCGACATCCTGACCCGACTGACCGCACCGGTGATCCGCGGC
CTGGGCATCGGCATCGTGCCGGCGGCTACCCGCGGTGGCCAGCGCAACCTGTTCACCGTC
GGCGCCACCCCCGAGGTTGCCCGGGCCTGGTCGAGCTACGCACCGACCGTGGTTCGCCTC
CCCGACGGCAGGGTCAAGCTCTCGACGAAGTTCACCCGGCTGACCGGCCGCTCGCCGATC
CTGCTCGCGGGCATGACCCCGACCACCGTGGACGCCAAGATCGTCGCCGCGGCGGCCAAC
GCCGGGCACTGGGCCGAGCTGGCCGGCGGCGGGCAGGTCACCGAAGAGATCTTCGGTAAC
CGCATCGAACAAATGGCCGGCCTGCTCGAGCCGGGCCGCACCTATCAGTTCAACGCGCTG
TTCCTCGATCCCTACCTGTGGAAGCTTCAGGTGGGCGGCAAGCGGTTGGTGCAGAAGGCC
CGCCAGTCCGGCGCCGCGATCGACGGCGTGGTGATCAGCGCCGGCATCCCAGACCTCGAC
GAGGCCGTCGAGCTGATCGACGAACTGGGCGACATCGGCATCAGCCACGTCGTGTTCAAA
CCCGGGACCATCGAGCAGATCCGCTCGGTGATTCGCATCGCCACCGAGGTGCCCACCAAG
CCGGTGATCATGCACGTCGAGGGCGGGCGCGCCGGCGGGCACCATTCCTGGGAGGATCTC
GACGACCTGCTGCTGGCTACCTACTCGGAGTTGCGCTCACGCGCCAACATCACGGTGTGC
GTCGGCGGCGGCATTGGCACCCCGAGAAGGGCTGCGGAATATTTGTCCGGGCGCTGGGCG
CAGGCCTACGGCTTCCCATTGATGCCGATCGACGGCATCCTGGTCGGCACCGCGGCGATG
GCCACCAAGGAATCCACCACGTCGCCATCGGTCAAGCGGATGCTCGTCGACACTCAGGGC
ACCGACCAATGGATCAGCGCCGGAAAAGCGCAGGGCGGCATGGCCTCCAGCCGCAGTCAG
CTCGGTGCCGATATCCACGAGATCGACAACAGCGCATCCCGGTGCGGGCGGCTGCTCGAC
GAGGTGGCCGGTGACGCGGAGGCGGTCGCGGAGCGTCGCGACGAGATCATCGCGGCGATG
GCCAAGACCGCCAAGCCCTACTTCGGCGACGTCGCCGACATGACCTACCTGCAGTGGCTG
CGGCGCTACGTCGAACTGGCCATCGGGGAAGGCAACTCGACCGCCGACACCGCCTCGGTG
GGCAGCCCGTGGCTGGCCGACACCTGGCGGGACCGCTTCGAGCAGATGCTGCAGCGTGCC
GAAGCCCGGTTGCACCCACAGGATTTCGGCCCGATCCAGACGCTATTCACCGATGCTGGC
CTGCTGGACAATCCGCAGCAGGCGATCGCCGCCCTGCTGGCGCGCTACCCCGACGCCGAG
ACCGTGCAGTTGCATCCCGCGGATGTGCCCTTTTTCGTGACGTTGTGCAAGACGCTGGGC
AAGCCGGTCAACTTCGTGCCGGTGATCGACCAGGACGTGCGGCGCTGGTGGCGCAGCGAC
TCGCTGTGGCAGGCCCACGACGCCCGCTACGACGCCGATGCGGTGTGCATCATTCCGGGC
ACCGCGTCGGTAGCCGGCATCACCCGGATGGATGAACCCGTCGGTGAGTTGCTGGACCGT
TTCGAGCAAGCCGCAATCGATGAAGTGCTCGGCGCCGGTGTCGAGCCGAAGGATGTCGCG
TCGCGCCGGCTGGGCCGCGCCGACGTGGCCGGACCGTTGGCTGTCGTCCTCGACGCACCC
GATGTGCGCTGGGCCGGTCGCACCGTGACCAACCCGGTGCATCGGATCGCCGACCCGGCC
GAATGGCAGGTGCACGATGGACCCGAAAACCCGCGCGCCACACACTCATCCACCGGCGCC
CGGCTGCAGACGCACGGCGACGACGTCGCCTTGAGCGTGCCCGTCTCGGGCACCTGGGTC
GACATCCGATTCACGTTGCCGGCCAACACCGTCGATGGCGGCACCCCGGTGATCGCCACC
GAGGACGCCACCAGCGCCATGCGCACGGTGCTGGCGATCGCCGCCGGTGTCGACAGCCCG
GAGTTCTTGCCTGCGGTGGCCAACGGGACGGCCACTTTGACGGTGGACTGGCACCCCGAG
CGTGTTGCCGACCACACCGGCGTCACCGCCACGTTCGGTGAGCCGCTGGCACCCAGCCTC
ACCAACGTGCCCGACGCGCTCGTCGGCCCTTGTTGGCCAGCGGTTTTCGCGGCCATCGGA
TCGGCGGTCACCGACACCGGTGAGCCGGTGGTGGAAGGCCTGCTGAGCCTGGTGCATCTG
GACCACGCCGCCCGCGTGGTCGGTCAGCTGCCCACGGTCCCGGCCCAATTGACCGTCACC
GCAACGGCTGCCAACGCAACCGATACGGACATGGGCCGCGTCGTGCCGGTCTCGGTCGTC
GTTACCGGCGCCGATGGCGCCGTGATCGCCACTCTCGAGGAGCGATTCGCGATCCTGGGT
CGCACCGGTTCCGCCGAGCTCGCCGACCCGGCGCGAGCCGGTGGCGCGGTGTCGGCGAAC
GCCACCGACACCCCGCGCCGTCGCCGCCGCGACGTCACGATCACCGCGCCGGTCGACATG
CGCCCGTTCGCGGTGGTGTCCGGCGACCACAACCCCATTCACACCGACCGGGCCGCCGCG
CTGCTTGCCGGCCTGGAGTCGCCGATCGTGCACGGCATGTGGCTGTCGGCCGCGGCGCAA
CACGCGGTGACCGCCACCGACGGGCAGGCCCGGCCACCGGCCCGGCTGGTCGGCTGGACC
GCGCGGTTTTTGGGCATGGTGCGCCCCGGCGACGAGGTGGACTTCCGCGTCGAGCGCGTC
GGAATCGACCAGGGCGCAGAGATTGTGGACGTGGCCGCGCGCGTCGGGTCGGATCTAGTG
ATGTCGGCCTCCGCGCGACTGGCCGCACCCAAGACGGTCTACGCATTCCCCGGCCAGGGC
ATCCAACACAAGGGCATGGGCATGGAGGTGCGCGCCCGCTCCAAGGCGGCCCGCAAGGTG
TGGGACACCGCGGACAAGTTCACCCGCGACACCCTGGGCTTCTCGGTACTGCACGTGGTC
CGCGACAACCCGACCAGCATCATCGCCAGCGGTGTGCACTACCACCACCCCGACGGGGTG
CTCTACCTGACGCAGTTCACCCAGGTCGCGATGGCGACGGTGGCGGCCGCGCAGGTCGCC
GAGATGCGTGAACAGGGAGCCTTCGTCGAAGGCGCCATCGCGTGCGGCCACTCGGTCGGC
GAGTACACCGCGCTGGCCTGCGTGACCGGCATCTACCAACTGGAAGCCTTGCTGGAGATG
GTGTTTCACCGCGGGTCGAAGATGCACGACATCGTTCCGCGCGACGAGCTCGGCCGCTCC
AACTATCGGCTGGCGGCCATCCGGCCGTCCCAGATCGACCTCGACGACGCCGACGTGCCC
GCGTTCGTCGCCGGGATCGCGGAGAGCACCGGTGAATTCCTGGAGATCGTGAATTTCAAC
CTGCGTGGCTCGCAATACGCGATCGCGGGCACGGTACGCGGCCTCGAGGCGCTCGAGGCC
GAGGTGGAGCGGCGCCGCGAGCTCACCGGCGGCCGACGGTCGTTCATTTTGGTGCCCGGC
ATCGATGTTCCGTTCCACTCGCGAGTGCTGCGGGTCGGGGTGGCCGAATTCCGGCGCTCG
CTGGACCGGGTCATGCCGCGCGACGCGGACCCCGACCTGATCATCGGGCGCTACATTCCC
AACCTGGTGCCGCGGTTGTTCACCCTGGACCGCGACTTCATCCAGGAAATCCGGGATTTG
GTGCCCGCCGAGCCGCTCGACGAGATCCTCGCCGACTACGACACCTGGCTTCGCGAGCGT
CCGCGCGAGATGGCGCGCACGGTGTTCATCGAGCTGCTGGCATGGCAATTCGCCAGCCCG
GTGCGCTGGATCGAGACGCAGGATCTGCTGTTCATCGAGGAGGCCGCCGGCGGGCTGGGT
GTGGAGCGATTCGTCGAGATCGGTGTGAAGAGCTCACCGACGGTGGCGGGTCTTGCCACC
AACACCCTCAAACTGCCCGAATACGCCCACAGCACAGTGGAAGTGCTCAACGCCGAGCGT
GATGCCGCGGTGCTGTTCGCCACCGACACCGACCCGGAGCCGGAGCCGGAGGAAGACGAG
CCGGTCGCGGAATCGCCCGCGCCGGACGTCGTCTCGGAAGCCGCCCCCGTCGCGCCGGCC
GCTTCGTCGGCGGGCCCGCGTCCCGACGATCTGGTTTTCGACGCCGCCGATGCCACGCTG
GCGCTGATCGCGCTCTCGGCCAAGATGCGCATCGACCAGATCGAAGAACTCGACTCCATC
GAGTCCATCACCGACGGTGCGTCGTCGCGGCGCAACCAGCTGCTGGTGGACCTGGGCTCC
GAGCTGAACCTCGGTGCCATTGACGGCGCCGCCGAATCGGACCTGGCCGGTCTGCGCTCA
CAGGTGACCAAACTGGCGCGCACCTACAAGCCTTACGGCCCAGTGCTTTCCGACGCCATC
AACGACCAGCTTCGCACCGTCCTCGGACCGTCGGGCAAGCGGCCCGGCGCCATCGCCGAG
CGGGTGAAGAAGACCTGGGAGCTCGGTGAGGGCTGGGCCAAGCATGTCACCGTCGAGGTC
GCGCTGGGCACCCGCGAGGGCAGCAGCGTTCGCGGCGGCGCCATGGGCCACCTGCACGAG
GGCGCGCTGGCCGATGCCGCCTCCGTCGACAAGGTCATCGACGCGGCGGTCGCATCGGTG
GCCGCGCGCCAGGGCGTTTCGGTAGCGCTGCCGTCGGCCGGTAGTGGTGGCGGCGCCACC
ATCGACGCGGCCGCGCTCAGCGAGTTCACCGACCAAATCACCGGCCGTGAGGGCGTGCTG
GCCTCCGCGGCCCGCCTGGTGCTGGGGCAGCTGGGACTGGACGACCCCGTCAACGCCTTG
CCGGCCGCCCCCGATTCCGAGCTGATCGACTTGGTCACCGCCGAACTGGGAGCGGACTGG
CCGCGGTTGGTGGCACCGGTGTTCGACCCCAAGAAGGCCGTCGTATTCGACGACCGCTGG
GCCAGCGCCCGCGAGGACCTGGTGAAGCTGTGGCTGACCGACGAGGGCGACATCGACGCC
GACTGGCCGCGCCTGGCGGAGCGCTTCGAGGGTGCCGGCCACGTCGTGGCGACCCAGGCT
ACCTGGTGGCAAGGTAAGTCGCTGGCCGCGGGCCGGCAGATCCATGCATCGCTGTACGGC
CGCATCGCCGCCGGCGCCGAGAACCCCGAACCCGGCCGCTACGGCGGCGAAGTTGCCGTG
GTGACCGGCGCTTCGAAGGGTTCGATCGCCGCGTCGGTGGTGGCTCGGCTGCTCGACGGC
GGAGCCACCGTCATCGCGACCACCTCCAAGCTCGACGAGGAGCGGCTGGCGTTCTACCGC
ACGCTGTATCGCGACCACGCCCGTTACGGCGCGGCGCTGTGGCTGGTCGCGGCGAACATG
GCGTCCTACTCCGACGTCGACGCCCTGGTCGAATGGATCGGCACCGAACAGACCGAAAGC
CTTGGGCCGCAGTCGATTCACATCAAAGACGCGCAGACCCCGACGCTGCTGTTCCCGTTC
GCGGCGCCACGCGTGGTCGGGGACCTGTCGGAGGCCGGTTCGCGCGCCGAGATGGAGATG
AAAGTGCTGCTGTGGGCCGTGCAACGGCTGATCGGCGGCCTGTCGACGATCGGCGCCGAA
CGCGACATCGCGTCGCGGCTGCACGTGGTGCTGCCCGGCTCGCCCAACCGTGGCATGTTC
GGCGGCGACGGCGCCTACGGCGAAGCCAAGTCCGCGCTGGATGCCGTGGTGAGCCGCTGG
CACGCCGAGTCGTCCTGGGCGGCACGGGTCAGCCTGGCGCACGCGCTCATCGGCTGGACC
CGCGGCACCGGGCTGATGGGCCACAACGATGCCATCGTGGCCGCCGTCGAAGAGGCCGGG
GTCACCACCTACTCGACCGACGAGATGGCGGCGCTGCTGCTCGACCTGTGTGATGCGGAA
TCCAAGGTGGCTGCGGCGCGTTCGCCGATCAAGGCCGACCTGACCGGGGGCCTGGCCGAG
GCCAACCTCGACATGGCCGAGCTGGCGGCCAAGGCGCGCGAGCAGATGTCGGCAGCGGCG
GCCGTCGACGAGGACGCCGAGGCCCCTGGCGCCATCGCCGCGCTGCCGTCGCCGCCCCGG
GGTTTCACCCCCGCACCGCCGCCGCAATGGGACGACCTCGATGTCGACCCGGCCGACCTG
GTGGTGATCGTCGGCGGCGCCGAAATCGGCCCGTACGGCTCGTCACGCACCCGGTTCGAG
ATGGAGGTCGAAAACGAGCTGTCGGCGGCCGGCGTGCTGGAGCTGGCCTGGACCACTGGG
TTGATCCGCTGGGAGGACGACCCGCAACCCGGTTGGTACGACACCGAATCCGGCGAAATG
GTCGACGAATCCGAGTTGGTGCAGCGCTACCACGACGCCGTGGTGCAGCGCGTCGGCATT
CGCGAATTCGTTGATGACGGCGCGATCGACCCCGACCACGCCTCGCCGCTGCTGGTGTCG
GTGTTCCTGGAGAAGGACTTCGCGTTCGTGGTGTCCTCGGAGGCCGATGCGCGCGCCTTC
GTCGAGTTCGATCCCGAGCACACGGTCATCCGGCCGGTGCCCGACTCCACCGACTGGCAG
GTCATCCGCAAGGCCGGCACCGAGATCCGGGTGCCGCGAAAGACCAAGCTGTCCCGCGTC
GTCGGCGGCCAGATCCCGACCGGGTTCGACCCGACGGTGTGGGGCATCAGCGCAGACATG
GCCGGTTCCATCGACCGGTTGGCGGTATGGAACATGGTGGCGACCGTCGACGCGTTCCTG
TCGTCCGGTTTCAGCCCGGCCGAGGTGATGCGTTACGTGCACCCGAGTTTGGTGGCCAAC
ACCCAGGGCACCGGCATGGGCGGCGGCACGTCGATGCAGACGATGTACCACGGCAATCTG
TTGGGCCGCAACAAGCCGAACGACATCTTCCAGGAAGTCTTGCCGAATATCATTGCCGCG
CACGTGGTTCAGTCCTACGTCGGTAGCTACGGTGCGATGATCCACCCGGTAGCCGCGTGC
GCCACCGCCGCGGTGTCGGTCGAGGAAGGTGTCGACAAGATCCGGTTGGGCAAGGCTCAA
CTGGTGGTGGCCGGCGGCCTGGATGACCTGACGCTGGAGGGCATCATCGGATTCGGTGAC
ATGGCCGCCACCGCCGACACGTCCATGATGTGCGGCCGCGGCATCCACGACTCGAAGTTT
TCCCGGCCCAACGACCGCCGCCGTCTGGGCTTCGTCGAAGCCCAAGGCGGCGGGACGATC
CTGTTGGCCCGCGGGGACCTGGCGCTGCGGATGGGGCTGCCGGTGCTGGCGGTGGTGGCG
TTCGCGCAGTCGTTCGGCGACGGCGTGCACACCTCGATCCCGGCCCCGGGCCTGGGCGCG
CTGGGGGCGGGCCGCGGCGGCAAGGATTCACCGCTGGCGCGGGCGCTGGCCAAGCTGGGC
GTGGCCGCCGACGACGTGGCGGTCATCTCCAAGCACGACACCTCGACGCTGGCCAACGAT
CCCAACGAGACCGAGTTGCATGAACGGCTCGCCGACGCCCTGGGCCGTTCCGAGGGCGCC
CCGCTGTTCGTGGTGTCGCAGAAGAGCCTGACCGGCCACGCCAAGGGCGGCGCGGCGGTC
TTCCAGATGATGGGGCTCTGCCAGATATTGCGGGATGGGGTGATCCCACCCAACCGCAGC
CTCGACTGCGTCGACGACGAGCTGGCCGGCTCCGCGCATTTCGTGTGGGTGCGTGACACG
TTGCGGCTCGGCGGCAAGTTCCCACTCAAGGCCGGCATGCTGACCAGCCTCGGGTTCGGC
CATGTGTCGGGCCTGGTCGCGTTGGTGCATCCGCAGGCGTTCATCGCCTCGCTGGATCCC
GCACAGCGCGCGGACTACCAGCGGCGTGCCGACGCCCGCCTGCTGGCCGGTCAGCGCCGG
CTGGCCTCGGCGATTGCCGGTGGTGCGCCGATGTACCAGCGGCCCGGTGACCGTCGCTTC
GACCACCACGCGCCCGAGCGGCCGCAGGAGGCGTCGATGCTGCTGAATCCGGCGGCCCGG
CTGGGTGACGGCGAGGCGTATATCGGCTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF01575</identifier>
            <name>MaoC_dehydratas</name>
          </pfam>
          <pfam>
            <identifier>PF00109</identifier>
            <name>ketoacyl-synt</name>
          </pfam>
          <pfam>
            <identifier>PF02801</identifier>
            <name>Ketoacyl-synt_C</name>
          </pfam>
          <pfam>
            <identifier>PF00698</identifier>
            <name>Acyl_transf_1</name>
          </pfam>
          <pfam>
            <identifier>PF08354</identifier>
            <name>DUF1729</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cell wall</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cytosol</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>fatty acid synthase complex</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>enoyl-[acyl-carrier-protein] reductase (NADH) activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>identical protein binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>fatty acid biosynthetic process</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="5">
      <id>BE0009715</id>
      <name>Uncharacterized MFS-type transporter EfpA</name>
      <organism>Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv)</organism>
      <actions>
        <action>other/unknown</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A182903</ref-id>
            <pubmed-id>19641733</pubmed-id>
            <citation>Manjunatha U, Boshoff HI, Barry CE: The mechanism of action of PA-824: Novel insights from transcriptional profiling. Commun Integr Biol. 2009 May;2(3):215-8. doi: 10.4161/cib.2.3.7926.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P9WJY5" source="Swiss-Prot">
        <name>Uncharacterized MFS-type transporter EfpA</name>
        <general-function/>
        <specific-function/>
        <gene-name>efpA</gene-name>
        <locus/>
        <cellular-location>Cell membrane</cellular-location>
        <transmembrane-regions>51-71
92-112
120-140
151-171
181-201
204-224
240-260
267-287
307-327
344-364
371-391
401-421
438-458
489-509</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi/>
        <molecular-weight>55578.955</molecular-weight>
        <chromosome-location/>
        <organism ncbi-taxonomy-id="83332">Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv)</organism>
        <external-identifiers>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P9WJY5</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>EFPA_MYCTU</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>Efflux protein A</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0052073|Uncharacterized MFS-type transporter EfpA
MTALNDTERAVRNWTAGRPHRPAPMRPPRSEETASERPSRYYPTWLPSRSFIAAVIAIGG
MQLLATMDSTVAIVALPKIQNELSLSDAGRSWVITAYVLTFGGLMLLGGRLGDTIGRKRT
FIVGVALFTISSVLCAVAWDEATLVIARLSQGVGSAIASPTGLALVATTFPKGPARNAAT
AVFAAMTAIGSVMGLVVGGALTEVSWRWAFLVNVPIGLVMIYLARTALRETNKERMKLDA
TGAILATLACTAAVFAFSIGPEKGWMSGITIGSGLVALAAAVAFVIVERTAENPVVPFHL
FRDRNRLVTFSAILLAGGVMFSLTVCIGLYVQDILGYSALRAGVGFIPFVIAMGIGLGVS
SQLVSRFSPRVLTIGGGYLLFGAMLYGSFFMHRGVPYFPNLVMPIVVGGIGIGMAVVPLT
LSAIAGVGFDQIGPVSAIALMLQSLGGPLVLAVIQAVITSRTLYLGGTTGPVKFMNDVQL
AALDHAYTYGLLWVAGAAIIVGGMALFIGYTPQQVAHAQEVKEAIDAGEL</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0052074|Uncharacterized MFS-type transporter EfpA (efpA)
ATGACGGCTCTCAACGACACAGAGCGGGCGGTCCGTAACTGGACAGCCGGACGCCCACAC
CGTCCGGCCCCGATGCGCCCGCCGCGCTCGGAGGAGACCGCTTCAGAGCGCCCCAGCAGG
TACTACCCGACTTGGCTGCCCTCGCGCAGCTTTATCGCTGCGGTTATTGCTATCGGCGGG
ATGCAGCTGCTGGCGACCATGGACAGCACCGTCGCCATCGTCGCGCTACCTAAGATTCAA
AACGAGCTGAGCTTGTCTGATGCCGGCCGCAGCTGGGTGATCACCGCCTACGTGCTGACC
TTCGGCGGGCTGATGCTGCTCGGCGGCCGGCTTGGCGACACCATCGGGCGCAAACGCACC
TTCATTGTTGGCGTTGCGCTATTCACCATCTCGTCGGTGCTGTGCGCGGTCGCCTGGGAC
GAGGCGACGTTGGTGATCGCCCGGTTGTCCCAGGGTGTGGGGTCGGCCATCGCATCTCCG
ACCGGTCTGGCGCTGGTGGCGACCACGTTCCCCAAGGGACCTGCCCGCAACGCCGCGACG
GCGGTGTTCGCCGCGATGACCGCGATCGGGTCGGTGATGGGGCTGGTGGTCGGCGGAGCA
CTGACCGAGGTGTCATGGCGGTGGGCGTTCCTGGTGAACGTGCCGATCGGGCTGGTGATG
ATCTACCTGGCCCGCACCGCCCTACGGGAAACCAACAAAGAACGGATGAAGCTCGACGCC
ACCGGGGCCATACTGGCCACGCTGGCATGCACCGCGGCGGTTTTCGCCTTCTCGATCGGT
CCTGAAAAGGGCTGGATGTCAGGCATTACCATCGGTTCGGGCCTGGTGGCCTTGGCGGCC
GCTGTCGCGTTTGTCATCGTGGAGCGCACTGCCGAGAACCCCGTCGTGCCGTTCCACTTG
TTCCGCGACCGCAACCGGTTGGTCACGTTCAGCGCGATCCTGTTGGCCGGCGGCGTCATG
TTCAGCCTGACCGTCTGCATCGGCCTGTACGTGCAGGACATCTTGGGCTACAGCGCGCTA
CGCGCGGGCGTAGGTTTCATCCCGTTCGTCATCGCGATGGGAATCGGCCTAGGTGTGTCC
TCGCAGCTGGTGTCCCGGTTTTCGCCACGGGTGTTGACCATCGGCGGCGGATATCTGCTA
TTCGGCGCCATGCTGTACGGCTCATTTTTCATGCACCGTGGTGTGCCCTACTTCCCCAAC
CTGGTCATGCCGATCGTCGTCGGCGGGATTGGCATCGGCATGGCCGTCGTCCCGCTGACT
CTGTCGGCGATCGCTGGCGTCGGCTTCGACCAGATCGGTCCGGTATCGGCAATTGCGCTG
ATGCTGCAGAGCCTGGGCGGTCCGCTGGTGCTCGCCGTCATCCAGGCTGTGATCACGTCG
CGCACGCTGTACCTGGGCGGTACCACCGGTCCGGTGAAGTTCATGAACGACGTGCAGTTG
GCCGCGCTTGACCACGCCTACACCTACGGCCTGCTGTGGGTGGCCGGAGCGGCCATCATC
GTCGGCGGTATGGCGCTGTTTATCGGGTATACGCCGCAGCAGGTTGCCCATGCGCAGGAG
GTCAAGGAAGCGATCGACGCCGGCGAGCTGTAA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF07690</identifier>
            <name>MFS_1</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>integral component of membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transmembrane transport</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="6">
      <id>BE0009714</id>
      <name>Nucleoid-associated protein Lsr2</name>
      <organism>Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv)</organism>
      <actions>
        <action>other/unknown</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A182903</ref-id>
            <pubmed-id>19641733</pubmed-id>
            <citation>Manjunatha U, Boshoff HI, Barry CE: The mechanism of action of PA-824: Novel insights from transcriptional profiling. Commun Integr Biol. 2009 May;2(3):215-8. doi: 10.4161/cib.2.3.7926.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P9WIP7" source="Swiss-Prot">
        <name>Nucleoid-associated protein Lsr2</name>
        <general-function>DNA-bridging protein that has both architectural and regulatory roles (PubMed:18187505). Influences the organization of chromatin and gene expression by binding non-specifically to DNA, with a preference for AT-rich sequences, and bridging distant DNA segments (PubMed:20133735). Binds in the minor groove of AT-rich DNA (PubMed:21673140). Represses expression of multiple genes involved in a broad range of cellular processes, including major virulence factors or antibiotic-induced genes, such as iniBAC or efpA (PubMed:17590082), and genes important for adaptation of changing O(2) levels (PubMed:24895305). May also activate expression of some gene (PubMed:24895305). May coordinate global gene regulation and virulence (PubMed:20133735). Also protects mycobacteria against reactive oxygen intermediates during macrophage infection by acting as a physical barrier to DNA degradation (PubMed:19237572); the physical protection has been questioned (PubMed:24895305). A strain overexpressing this protein consumes O(2) more slowly than wild-type (PubMed:24895305).</general-function>
        <specific-function>Dna binding</specific-function>
        <gene-name>lsr2</gene-name>
        <locus/>
        <cellular-location>Cytoplasm</cellular-location>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi/>
        <molecular-weight>12098.335</molecular-weight>
        <chromosome-location/>
        <organism ncbi-taxonomy-id="83332">Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv)</organism>
        <external-identifiers>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P9WIP7</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>LSR2_MYCTU</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms/>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0052071|Nucleoid-associated protein Lsr2
MAKKVTVTLVDDFDGSGAADETVEFGLDGVTYEIDLSTKNATKLRGDLKQWVAAGRRVGG
RRRGRSGSGRGRGAIDREQSAAIREWARRNGHNVSTRGRIPADVIDAYHAAT</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0052072|Nucleoid-associated protein Lsr2 (lsr2)
ATGGCGAAGAAAGTAACCGTCACCTTGGTCGACGATTTCGACGGTTCGGGCGCCGCCGAC
GAAACGGTCGAATTCGGGCTTGACGGGGTGACCTATGAGATCGACCTTTCCACTAAGAAT
GCCACGAAACTGCGTGGCGACCTGAAGCAATGGGTGGCGGCGGGCCGTCGCGTCGGTGGG
CGCCGGCGCGGCCGTTCCGGATCCGGCCGTGGACGTGGCGCGATCGACCGCGAGCAGAGC
GCGGCGATCCGCGAATGGGCTCGTCGTAACGGGCACAATGTGTCGACGCGAGGCCGGATC
CCGGCCGACGTCATCGACGCATACCACGCGGCGACCTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF11774</identifier>
            <name>Lsr2</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cell wall</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cytosol</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nucleoid</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>DNA binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to oxygen levels</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>DNA protection</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>pathogenesis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of transcription, DNA-templated</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to hydrogen peroxide</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to iron ion</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="7">
      <id>BE0009716</id>
      <name>Cyd operon, Mycobacterium tuberculosis</name>
      <organism>Mycobacterium tuberculosis</organism>
      <actions>
        <action>other/unknown</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A182903</ref-id>
            <pubmed-id>19641733</pubmed-id>
            <citation>Manjunatha U, Boshoff HI, Barry CE: The mechanism of action of PA-824: Novel insights from transcriptional profiling. Commun Integr Biol. 2009 May;2(3):215-8. doi: 10.4161/cib.2.3.7926.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="A0A0T9AZ62" source="TrEMBL">
        <name>ABC transporter ATP-binding protein</name>
        <general-function/>
        <specific-function>Atp binding</specific-function>
        <gene-name>cydC</gene-name>
        <locus/>
        <cellular-location/>
        <transmembrane-regions>31-49
120-142</transmembrane-regions>
        <signal-regions>1-30</signal-regions>
        <theoretical-pi/>
        <molecular-weight>45132.465</molecular-weight>
        <chromosome-location/>
        <organism ncbi-taxonomy-id="1773">Mycobacterium tuberculosis</organism>
        <external-identifiers>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>A0A0T9AZ62</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>A0A0T9AZ62_MYCTX</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms/>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0052082|ABC transporter ATP-binding protein
MLVRALVPIAVAAVLAVAATAVVAAVSVPAAVVLAVCLLVAGVVAPWLAGRTAAAQEAIA
RQHRGMRDTSAMIALEHAPELRVAGALRNVIADSQRRQHAWADALDAAARTGAIAEAMPT
AAIGASLLGAVVAGIGMAPTVAPTTLAILMLLPLSAFEATVALPAAAVQLTRSRIAAARL
LDLTGSNRVRETESTVSARLPVGTGVLAADVCCGHQEAQSIRVTIDLPPGARLAVTGASG
AGKTTLLMTLAGLLPPVHGRVLLDGTNLSDFDEDELRSAVSFFAEDAHIFATTVRDNLLT
ARGDCPDDELIEALDRVGLCGWLAGLPEGLSTVLIGGAQAVSAGQRRRLLLARAVLSPAR
IVLLDEPVEHLDAANADLLRDLLAPNSGIMSAMRTVVVATHHLPNDIQCAELSIATDQRC
RRRGTNSSDNNTNASAKT</amino-acid-sequence>
        <gene-sequence format="FASTA"/>
        <pfams>
          <pfam>
            <identifier>PF00005</identifier>
            <name>ABC_tran</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cell</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>ATP binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>ATPase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>ATPase-coupled transmembrane transporter activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cell redox homeostasis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>glutathione transmembrane transport</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <polypeptide id="A0A1K3GRG2" source="TrEMBL">
        <name>Cyd operon protein YbgE</name>
        <general-function/>
        <specific-function/>
        <gene-name/>
        <locus/>
        <cellular-location/>
        <transmembrane-regions>12-31
43-65
74-93</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi/>
        <molecular-weight>10518.555</molecular-weight>
        <chromosome-location/>
        <organism ncbi-taxonomy-id="1773">Mycobacterium tuberculosis</organism>
        <external-identifiers>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>A0A1K3GRG2</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>A0A1K3GRG2_MYCTX</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms/>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0052079|Cyd operon protein YbgE
MLDKSYQLLDKGPLRALVLIMALGLALSVIWDPSRFAANTSSLQIWQGLLMIWAVCSGAI
FGLAFRPKRAIWKILFHPLPAVVILGYGLYHFFS</amino-acid-sequence>
        <gene-sequence format="FASTA"/>
        <pfams>
          <pfam>
            <identifier>PF09600</identifier>
            <name>Cyd_oper_YbgE</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>integral component of membrane</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <polypeptide id="A0A045KKX4" source="TrEMBL">
        <name>Cytochrome D ubiquinol oxidase subunit I</name>
        <general-function/>
        <specific-function>Electron transfer activity</specific-function>
        <gene-name>cydA</gene-name>
        <locus/>
        <cellular-location>Cell inner membrane</cellular-location>
        <transmembrane-regions>20-41
53-71
91-115
127-150
187-208
220-242
339-361
373-394
429-451</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi/>
        <molecular-weight>53826.08</molecular-weight>
        <chromosome-location/>
        <organism ncbi-taxonomy-id="1773">Mycobacterium tuberculosis</organism>
        <external-identifiers>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>A0A045KKX4</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>A0A045KKX4_MYCTX</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>cydA_3</synonym>
          <synonym>Cytochrome ubiquinol oxidase subunit I</synonym>
          <synonym>Putative integral membrane cytochrome D ubiquinol oxidase (Subunit I) CydA (Cytochrome BD-I oxidase subunit I)</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0052080|Cytochrome D ubiquinol oxidase subunit I
MNVVDISRWQFGITTVYHFIFVPLTIGLAPLIAVMQTLWVVTDNPAWYRLTKFFGKLFLI
NFAIGVATGIVQEFQFGMNWSEYSRFVGDVFGAPLAMEGLAAFFFESTFIGLWIFGWNRL
PRLVHLACIWIVAIAVNVSAFFIIAANSFMQHPVGAHYNPTTGRAELSSIVVLLTNNTAQ
AAFTHTVSGALLTAGTFVAAVSAWWLVRSSTTHADSDTQAMYRPATILGCWVALAATAGL
LFTGDHQGKLMFQQQPMKMASAESLCDTQTDPNFSVLTVGRQNNCDSLTRVIEVPYVLPF
LAEGRISGVTLQGIRDLQQEYQQRFGPNDYRPNLFVTYWSFRMMIGLMAIPVLFALIALW
LTRGGQIPNQRWFSWLALLTMPAPFLANSAGWVFTEMGRQPWVVVPNPTGDQLVRLTVKA
GVSDHSATVVATSLLMFTLVYAVLAVIWCWLLKRYIVEGPLEHDAEPAAHGAPRDDEVAP
LSFAY</amino-acid-sequence>
        <gene-sequence format="FASTA"/>
        <pfams>
          <pfam>
            <identifier>PF01654</identifier>
            <name>Cyt_bd_oxida_I</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cytochrome complex</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>electron transfer activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>metal ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>aerobic electron transport chain</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <polypeptide id="A0A045ISQ8" source="TrEMBL">
        <name>Cytochrome D Ubiquinol oxidase subunit II</name>
        <general-function/>
        <specific-function>Oxidoreductase activity</specific-function>
        <gene-name>cydB</gene-name>
        <locus/>
        <cellular-location/>
        <transmembrane-regions>6-24
87-107
119-142
162-188
200-221
227-247
254-275
303-326</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi/>
        <molecular-weight>37626.835</molecular-weight>
        <chromosome-location/>
        <organism ncbi-taxonomy-id="1773">Mycobacterium tuberculosis</organism>
        <external-identifiers>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>A0A045ISQ8</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>A0A045ISQ8_MYCTX</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>cydB_1</synonym>
          <synonym>cydB_2</synonym>
          <synonym>Putative integral membrane cytochrome D ubiquinol oxidase (Subunit II) CydB (Cytochrome BD-I oxidase subunit II)</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0052081|Cytochrome D Ubiquinol oxidase subunit II
MVLQELWFGVIAALFLGFFILEGFDFGVGMLMAPFAHVGMGDPETHRRTALNTIGPVWDG
NEVWLITAGAAIFAAFPGWYATVFSALYLPLLAILFGMILRAVAIEWRGKIDDPKWRTGA
DFGIAAGSWLPALLWGVAFAILVRGLPVDANGHVALSIPDVLNAYTLLGGLATAGLFSLY
GAVFIALKTSGPIRDDAYRFAVWLSLPVAGLVAGFGLWTQLAYGKDWTWLVLAVAGCAQA
AATVLVWRRVSDGWAFMCTLIVVAAVVVLLFGALYPNLVPSTLNPQWSLTIHNASSTPYT
LKIMTWVTAFFAPLTVAYQTWTYWVFRQRISAERIPPPTGLARRAP</amino-acid-sequence>
        <gene-sequence format="FASTA"/>
        <pfams>
          <pfam>
            <identifier>PF02322</identifier>
            <name>Cyt_bd_oxida_II</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>integral component of membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>oxidoreductase activity</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="8">
      <id>BE0000332</id>
      <name>Enoyl-[acyl-carrier-protein] reductase [NADH]</name>
      <organism>Mycobacterium tuberculosis</organism>
      <actions>
        <action>other/unknown</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A182903</ref-id>
            <pubmed-id>19641733</pubmed-id>
            <citation>Manjunatha U, Boshoff HI, Barry CE: The mechanism of action of PA-824: Novel insights from transcriptional profiling. Commun Integr Biol. 2009 May;2(3):215-8. doi: 10.4161/cib.2.3.7926.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P9WGR1" source="Swiss-Prot">
        <name>Enoyl-[acyl-carrier-protein] reductase [NADH]</name>
        <general-function>Enoyl-ACP reductase of the type II fatty acid syntase (FAS-II) system, which is involved in the biosynthesis of mycolic acids, a major component of mycobacterial cell walls (PubMed:25227413). Catalyzes the NADH-dependent reduction of the double bond of 2-trans-enoyl-[acyl-carrier protein], an essential step in the fatty acid elongation cycle of the FAS-II pathway (PubMed:7599116). Shows preference for long-chain fatty acyl thioester substrates (&gt;C16), and can also use 2-trans-enoyl-CoAs as alternative substrates (PubMed:7599116). The mycobacterial FAS-II system utilizes the products of the FAS-I system as primers to extend fatty acyl chain lengths up to C56, forming the meromycolate chain that serves as the precursor for final mycolic acids (PubMed:25227413).</general-function>
        <specific-function>Enoyl-[acyl-carrier-protein] reductase (nadh) activity</specific-function>
        <gene-name>inhA</gene-name>
        <locus/>
        <cellular-location/>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi/>
        <molecular-weight>28527.55</molecular-weight>
        <chromosome-location/>
        <organism ncbi-taxonomy-id="83332">Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv)</organism>
        <external-identifiers>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P9WGR1</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>INHA_MYCTU</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>1.3.1.9</synonym>
          <synonym>ENR</synonym>
          <synonym>FAS-II enoyl-ACP reductase</synonym>
          <synonym>NADH-dependent 2-trans-enoyl-ACP reductase</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0051173|Enoyl-[acyl-carrier-protein] reductase [NADH]
MTGLLDGKRILVSGIITDSSIAFHIARVAQEQGAQLVLTGFDRLRLIQRITDRLPAKAPL
LELDVQNEEHLASLAGRVTEAIGAGNKLDGVVHSIGFMPQTGMGINPFFDAPYADVSKGI
HISAYSYASMAKALLPIMNPGGSIVGMDFDPSRAMPAYNWMTVAKSALESVNRFVAREAG
KYGVRSNLVAAGPIRTLAMSAIVGGALGEEAGAQIQLLEEGWDQRAPIGWNMKDATPVAK
TVCALLSDWLPATTGDIIYADGGAHTQLL</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0051174|Enoyl-[acyl-carrier-protein] reductase [NADH] (inhA)
ATGACAGGACTGCTGGACGGCAAACGGATTCTGGTTAGCGGAATCATCACCGACTCGTCG
ATCGCGTTTCACATCGCACGGGTAGCCCAGGAGCAGGGCGCCCAGCTGGTGCTCACCGGG
TTCGACCGGCTGCGGCTGATTCAGCGCATCACCGACCGGCTGCCGGCAAAGGCCCCGCTG
CTCGAACTCGACGTGCAAAACGAGGAGCACCTGGCCAGCTTGGCCGGCCGGGTGACCGAG
GCGATCGGGGCGGGCAACAAGCTCGACGGGGTGGTGCATTCGATTGGGTTCATGCCGCAG
ACCGGGATGGGCATCAACCCGTTCTTCGACGCGCCCTACGCGGATGTGTCCAAGGGCATC
CACATCTCGGCGTATTCGTATGCTTCGATGGCCAAGGCGCTGCTGCCGATCATGAACCCC
GGAGGTTCCATCGTCGGCATGGACTTCGACCCGAGCCGGGCGATGCCGGCCTACAACTGG
ATGACGGTCGCCAAGAGCGCGTTGGAGTCGGTCAACAGGTTCGTGGCGCGCGAGGCCGGC
AAGTACGGTGTGCGTTCGAATCTCGTTGCCGCAGGCCCTATCCGGACGCTGGCGATGAGT
GCGATCGTCGGCGGTGCGCTCGGCGAGGAGGCCGGCGCCCAGATCCAGCTGCTCGAGGAG
GGCTGGGATCAGCGCGCTCCGATCGGCTGGAACATGAAGGATGCGACGCCGGTCGCCAAG
ACGGTGTGCGCGCTGCTGTCTGACTGGCTGCCGGCGACCACGGGTGACATCATCTACGCC
GACGGCGGCGCGCACACCCAATTGCTCTAG</gene-sequence>
        <pfams/>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cell wall</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>enoyl-[acyl-carrier-protein] reductase (NADH) activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>fatty acid binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>NAD+ binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>fatty acid elongation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>mycolic acid biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to antibiotic</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
  </targets>
  <enzymes>
    <enzyme position="1">
      <id>BE0002638</id>
      <name>Cytochrome P450 3A4</name>
      <organism>Humans</organism>
      <actions>
        <action>substrate</action>
      </actions>
      <references>
        <articles/>
        <textbooks/>
        <links>
          <link>
            <ref-id>L8057</ref-id>
            <title>Pretomanid briefing document, FDA</title>
            <url>https://www.fda.gov/media/127592/download</url>
          </link>
          <link>
            <ref-id>L8048</ref-id>
            <title>Pretomanid FDA label, August 2019</title>
            <url>https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212862s000lbl.pdf</url>
          </link>
        </links>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P08684" source="Swiss-Prot">
        <name>Cytochrome P450 3A4</name>
        <general-function>Vitamin d3 25-hydroxylase activity</general-function>
        <specific-function>Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Acts as a 1,8-cineole 2-exo-monooxygenase. The enzyme also hydroxylates etoposide (PubMed:11159812). Catalyzes 4-beta-hydroxylation of cholesterol. May catalyze 25-hydroxylation of cholesterol in vitro (PubMed:21576599).</specific-function>
        <gene-name>CYP3A4</gene-name>
        <locus>7q21.1</locus>
        <cellular-location>Endoplasmic reticulum membrane</cellular-location>
        <transmembrane-regions>2-22</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>8.25</theoretical-pi>
        <molecular-weight>57342.67</molecular-weight>
        <chromosome-location>7</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:2637</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>CYP3A4</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>M18907</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>1337</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P08684</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>CP3A4_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>1,8-cineole 2-exo-monooxygenase</synonym>
          <synonym>1.14.13.-</synonym>
          <synonym>Albendazole monooxygenase</synonym>
          <synonym>Albendazole sulfoxidase</synonym>
          <synonym>Cholesterol 25-hydroxylase</synonym>
          <synonym>CYP3A3</synonym>
          <synonym>CYPIIIA3</synonym>
          <synonym>CYPIIIA4</synonym>
          <synonym>Cytochrome P450 3A3</synonym>
          <synonym>Cytochrome P450 HLp</synonym>
          <synonym>Cytochrome P450 NF-25</synonym>
          <synonym>Cytochrome P450-PCN1</synonym>
          <synonym>Nifedipine oxidase</synonym>
          <synonym>Quinine 3-monooxygenase</synonym>
          <synonym>Taurochenodeoxycholate 6-alpha-hydroxylase</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0021936|Cytochrome P450 3A4
MALIPDLAMETWLLLAVSLVLLYLYGTHSHGLFKKLGIPGPTPLPFLGNILSYHKGFCMF
DMECHKKYGKVWGFYDGQQPVLAITDPDMIKTVLVKECYSVFTNRRPFGPVGFMKSAISI
AEDEEWKRLRSLLSPTFTSGKLKEMVPIIAQYGDVLVRNLRREAETGKPVTLKDVFGAYS
MDVITSTSFGVNIDSLNNPQDPFVENTKKLLRFDFLDPFFLSITVFPFLIPILEVLNICV
FPREVTNFLRKSVKRMKESRLEDTQKHRVDFLQLMIDSQNSKETESHKALSDLELVAQSI
IFIFAGYETTSSVLSFIMYELATHPDVQQKLQEEIDAVLPNKAPPTYDTVLQMEYLDMVV
NETLRLFPIAMRLERVCKKDVEINGMFIPKGVVVMIPSYALHRDPKYWTEPEKFLPERFS
KKNKDNIDPYIYTPFGSGPRNCIGMRFALMNMKLALIRVLQNFSFKPCKETQIPLKLSLG
GLLQPEKPVVLKVESRDGTVSGA</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0021937|Cytochrome P450 3A4 (CYP3A4)
ATGGCTCTCATCCCAGACTTGGCCATGGAAACCTGGCTTCTCCTGGCTGTCAGCCTGGTG
CTCCTCTATCTATATGGAACCCATTCACATGGACTTTTTAAGAAGCTTGGAATTCCAGGG
CCCACACCTCTGCCTTTTTTGGGAAATATTTTGTCCTACCATAAGGGCTTTTGTATGTTT
GACATGGAATGTCATAAAAAGTATGGAAAAGTGTGGGGCTTTTATGATGGTCAACAGCCT
GTGCTGGCTATCACAGATCCTGACATGATCAAAACAGTGCTAGTGAAAGAATGTTATTCT
GTCTTCACAAACCGGAGGCCTTTTGGTCCAGTGGGATTTATGAAAAGTGCCATCTCTATA
GCTGAGGATGAAGAATGGAAGAGATTACGATCATTGCTGTCTCCAACCTTCACCAGTGGA
AAACTCAAGGAGATGGTCCCTATCATTGCCCAGTATGGAGATGTGTTGGTGAGAAATCTG
AGGCGGGAAGCAGAGACAGGCAAGCCTGTCACCTTGAAAGACGTCTTTGGGGCCTACAGC
ATGGATGTGATCACTAGCACATCATTTGGAGTGAACATCGACTCTCTCAACAATCCACAA
GACCCCTTTGTGGAAAACACCAAGAAGCTTTTAAGATTTGATTTTTTGGATCCATTCTTT
CTCTCAATAATCTTTCCATTCCTCATCCCAATTCTTGAAGTATTAAATATCTGTGTGTTT
CCAAGAGAAGTTACAAATTTTTTAAGAAAATCTGTAAAAAGGATGAAAGAAAGTCGCCTC
GAAGATACACAAAAGCACCGAGTGGATTTCCTTCAGCTGATGATTGACTCTCAGAATTCA
AAAGAAACTGAGTCCCACAAAGCTCTGTCCGATCTGGAGCTCGTGGCCCAATCAATTATC
TTTATTTTTGCTGGCTATGAAACCACGAGCAGTGTTCTCTCCTTCATTATGTATGAACTG
GCCACTCACCCTGATGTCCAGCAGAAACTGCAGGAGGAAATTGATGCAGTTTTACCCAAT
AAGGCACCACCCACCTATGATACTGTGCTACAGATGGAGTATCTTGACATGGTGGTGAAT
GAAACGCTCAGATTATTCCCAATTGCTATGAGACTTGAGAGGGTCTGCAAAAAAGATGTT
GAGATCAATGGGATGTTCATTCCCAAAGGGGTGGTGGTGATGATTCCAAGCTATGCTCTT
CACCGTGACCCAAAGTACTGGACAGAGCCTGAGAAGTTCCTCCCTGAAAGATTCAGCAAG
AAGAACAAGGACAACATAGATCCTTACATATACACACCCTTTGGAAGTGGACCCAGAAAC
TGCATTGGCATGAGGTTTGCTCTCATGAACATGAAACTTGCTCTAATCAGAGTCCTTCAG
AACTTCTCCTTCAAACCTTGTAAAGAAACACAGATCCCCCTGAAATTAAGCTTAGGAGGA
CTTCTTCAACCAGAAAAACCCGTTGTTCTAAAGGTTGAGTCAAGGGATGGCACCGTAAGT
GGAGCCTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00067</identifier>
            <name>p450</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cytoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>endoplasmic reticulum membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>intracellular membrane-bounded organelle</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>albendazole monooxygenase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>aromatase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>caffeine oxidase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>enzyme binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>heme binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>iron ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>monooxygenase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>oxidoreductase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>oxygen binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>quinine 3-monooxygenase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>steroid binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>steroid hydroxylase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>taurochenodeoxycholate 6alpha-hydroxylase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>testosterone 6-beta-hydroxylase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>vitamin D 24-hydroxylase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>vitamin D3 25-hydroxylase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>alkaloid catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>androgen metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>calcitriol biosynthetic process from calciol</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>drug catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>drug metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>exogenous drug catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>heterocycle metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>lipid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>monoterpenoid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>oxidation-reduction process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>oxidative demethylation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small molecule metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>steroid catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>steroid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>vitamin D metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>xenobiotic metabolic process</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <inhibition-strength/>
      <induction-strength/>
    </enzyme>
    <enzyme position="2">
      <id>BE0009325</id>
      <name>Deazaflavin-dependent nitroreductase</name>
      <organism>Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv)</organism>
      <actions>
        <action>substrate</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A182903</ref-id>
            <pubmed-id>19641733</pubmed-id>
            <citation>Manjunatha U, Boshoff HI, Barry CE: The mechanism of action of PA-824: Novel insights from transcriptional profiling. Commun Integr Biol. 2009 May;2(3):215-8. doi: 10.4161/cib.2.3.7926.</citation>
          </article>
          <article>
            <ref-id>A182897</ref-id>
            <pubmed-id>29259747</pubmed-id>
            <citation>Thompson AM, Bonnet M, Lee HH, Franzblau SG, Wan B, Wong GS, Cooper CB, Denny WA: Antitubercular Nitroimidazoles Revisited: Synthesis and Activity of the Authentic 3-Nitro Isomer of Pretomanid. ACS Med Chem Lett. 2017 Nov 13;8(12):1275-1280. doi: 10.1021/acsmedchemlett.7b00356. eCollection 2017 Dec 14.</citation>
          </article>
        </articles>
        <textbooks/>
        <links>
          <link>
            <ref-id>L8048</ref-id>
            <title>Pretomanid FDA label, August 2019</title>
            <url>https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212862s000lbl.pdf</url>
          </link>
        </links>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P9WP15" source="Swiss-Prot">
        <name>Deazaflavin-dependent nitroreductase</name>
        <general-function>Involved in a F420-dependent anti-oxidant mechanism that protects M.tuberculosis against oxidative stress and bactericidal agents. Catalyzes the F420H(2)-dependent two-electron reduction of quinones to dihydroquinones, thereby preventing the formation of cytotoxic semiquinones obtained by the one-electron reduction pathway (PubMed:23240649). In vitro, catalyzes the reduction of both benzoquinone and naphthoquinone analogs; since menaquinone is the sole quinone electron carrier in the respiratory chain in M.tuberculosis, the physiological electron acceptor for Fqr-mediated F420H(2) oxidation is therefore likely to be the endogenous menaquinone found in the membrane fraction of M.tuberculosis (PubMed:23240649). Is able to use F420 species with two and five glutamate residues in its polyglutamate tail (PubMed:22023140). Cannot use NADH or NADPH instead of F420H(2) as the electron donor (PubMed:23240649).</general-function>
        <specific-function>Coenzyme f420 binding</specific-function>
        <gene-name>ddn</gene-name>
        <locus/>
        <cellular-location>Cell membrane</cellular-location>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi/>
        <molecular-weight>17370.87</molecular-weight>
        <chromosome-location/>
        <organism ncbi-taxonomy-id="83332">Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv)</organism>
        <external-identifiers>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P9WP15</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>DDN_MYCTU</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>1.-.-.-</synonym>
          <synonym>F420H(2)-dependent quinone reductase Ddn</synonym>
          <synonym>Fqr</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0051576|Deazaflavin-dependent nitroreductase
MPKSPPRFLNSPLSDFFIKWMSRINTWMYRRNDGEGLGGTFQKIPVALLTTTGRKTGQPR
VNPLYFLRDGGRVIVAASKGGAEKNPMWYLNLKANPKVQVQIKKEVLDLTARDATDEERA
EYWPQLVTMYPSYQDYQSWTDRTIPIVVCEP</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0051577|Deazaflavin-dependent nitroreductase (ddn)
ATGCCGAAATCACCGCCGCGGTTTCTGAATTCGCCGCTCAGCGACTTCTTTATCAAGTGG
ATGTCACGGATTAATACCTGGATGTACCGCCGCAACGACGGGGAGGGTCTGGGCGGCACC
TTCCAGAAGATTCCGGTCGCGCTGCTGACCACCACCGGCCGCAAGACCGGCCAGCCGCGG
GTCAACCCGCTCTACTTCCTGCGCGACGGTGGGCGGGTCATTGTCGCGGCCTCCAAGGGC
GGCGCGGAGAAGAACCCGATGTGGTACCTCAACCTCAAGGCCAACCCCAAGGTTCAGGTA
CAGATCAAAAAGGAAGTGCTGGACCTTACCGCGCGGGACGCGACCGACGAGGAGCGCGCC
GAATATTGGCCACAGTTGGTCACGATGTACCCAAGTTATCAGGACTACCAGTCCTGGACC
GACCGCACGATCCCGATCGTGGTTTGCGAACCCTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF04075</identifier>
            <name>F420H2_quin_red</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cell wall</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>coenzyme F420 binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>oxidoreductase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>oxidation-reduction process</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <inhibition-strength/>
      <induction-strength/>
    </enzyme>
  </enzymes>
  <carriers/>
  <transporters>
    <transporter position="3">
      <id>BE0003645</id>
      <name>Solute carrier family 22 member 8</name>
      <organism>Humans</organism>
      <actions>
        <action>inhibitor</action>
      </actions>
      <references>
        <articles/>
        <textbooks/>
        <links>
          <link>
            <ref-id>L8048</ref-id>
            <title>Pretomanid FDA label, August 2019</title>
            <url>https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212862s000lbl.pdf</url>
          </link>
          <link>
            <ref-id>L8057</ref-id>
            <title>Pretomanid briefing document, FDA</title>
            <url>https://www.fda.gov/media/127592/download</url>
          </link>
        </links>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="Q8TCC7" source="Swiss-Prot">
        <name>Solute carrier family 22 member 8</name>
        <general-function>Sodium-independent organic anion transmembrane transporter activity</general-function>
        <specific-function>Plays an important role in the excretion/detoxification of endogenous and exogenous organic anions, especially from the brain and kidney. Involved in the transport basolateral of steviol, fexofenadine. Transports benzylpenicillin (PCG), estrone-3-sulfate (E1S), cimetidine (CMD), 2,4-dichloro-phenoxyacetate (2,4-D), p-amino-hippurate (PAH), acyclovir (ACV) and ochratoxin (OTA).</specific-function>
        <gene-name>SLC22A8</gene-name>
        <locus>11q11</locus>
        <cellular-location>Basolateral cell membrane</cellular-location>
        <transmembrane-regions>10-30
124-144
155-175
177-197
213-233
237-257
328-348
355-375
387-407
412-432
472-492</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>9.05</theoretical-pi>
        <molecular-weight>59855.585</molecular-weight>
        <chromosome-location>11</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:10972</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>AF097491</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>4378059</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>1027</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>Q8TCC7</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>S22A8_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>hOAT3</synonym>
          <synonym>OAT3</synonym>
          <synonym>Organic anion transporter 3</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0007005|Solute carrier family 22 member 8
MTFSEILDRVGSMGHFQFLHVAILGLPILNMANHNLLQIFTAATPVHHCRPPHNASTGPW
VLPMGPNGKPERCLRFVHPPNASLPNDTQRAMEPCLDGWVYNSTKDSIVTEWDLVCNSNK
LKEMAQSIFMAGILIGGLVLGDLSDRFGRRPILTCSYLLLAASGSGAAFSPTFPIYMVFR
FLCGFGISGITLSTVILNVEWVPTRMRAIMSTALGYCYTFGQFILPGLAYAIPQWRWLQL
TVSIPFFVFFLSSWWTPESIRWLVLSGKSSKALKILRRVAVFNGKKEEGERLSLEELKLN
LQKEISLAKAKYTASDLFRIPMLRRMTFCLSLAWFATGFAYYSLAMGVEEFGVNLYILQI
IFGGVDVPAKFITILSLSYLGRHTTQAAALLLAGGAILALTFVPLDLQTVRTVLAVFGKG
CLSSSFSCLFLYTSELYPTVIRQTGMGVSNLWTRVGSMVSPLVKITGEVQPFIPNIIYGI
TALLGGSAALFLPETLNQPLPETIEDLENWSLRAKKPKQEPEVEKASQRIPLQPHGPGLG
SS</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0019450|Solute carrier family 22 member 8 (SLC22A8)
ATGACCTTCTCGGAGATCCTGGACCGTGTGGGAAGCATGGGCCATTTCCAGTTCCTGCAT
GTAGCCATACTGGGCCTCCCGATCCTCAACATGGCCAACCACAACCTGCTGCAGATCTTC
ACAGCCGCCACCCCTGTCCACCACTGTCGCCCGCCCCACAATGCCTCCACAGGGCCTTGG
GTGCTCCCCATGGGCCCAAATGGGAAGCCTGAGAGGTGCCTCCGTTTTGTACATCCGCCC
AATGCCAGCCTGCCCAATGACACCCAGAGGGCCATGGAGCCATGCCTGGATGGCTGGGTC
TACAACAGCACCAAGGACTCCATTGTGACAGAGTGGGACTTGGTGTGCAACTCCAACAAA
CTGAAGGAGATGGCCCAGTCTATCTTCATGGCAGGTATACTGATTGGAGGGCTCGTGCTT
GGAGACCTGTCTGACAGGTTTGGCCGCAGGCCCATCCTGACCTGCAGCTACCTGCTGCTG
GCAGCCAGCGGCTCCGGTGCAGCCTTCAGCCCCACCTTCCCCATCTACATGGTCTTCCGC
TTCCTGTGTGGCTTTGGCATCTCAGGCATTACCCTGAGCACCGTCATCTTGAATGTGGAA
TGGGTGCCTACCCGGATGCGGGCCATCATGTCGACAGCACTCGGGTACTGCTACACCTTT
GGCCAGTTCATTCTGCCCGGCCTGGCCTACGCCATCCCCCAGTGGCGTTGGCTGCAGTTA
ACTGTGTCCATTCCCTTCTTCGTCTTCTTCCTATCATCCTGGTGGACACCAGAGTCCATA
CGCTGGTTGGTCTTGTCTGGAAAGTCCTCGAAGGCCCTGAAGATACTCCGGCGGGTGGCT
GTCTTCAATGGCAAGAAGGAAGAGGGAGAAAGGCTCAGCTTGGAGGAGCTCAAACTCAAC
CTGCAGAAGGAGATCTCCTTGGCCAAGGCCAAGTACACCGCAAGTGACCTGTTCCGGATA
CCCATGCTGCGCCGCATGACCTTCTGTCTTTCCCTGGCCTGGTTTGCTACCGGTTTTGCC
TACTATAGTTTGGCTATGGGTGTGGAAGAATTTGGAGTCAACCTCTACATCCTCCAGATC
ATCTTTGGTGGGGTCGATGTCCCAGCCAAGTTCATCACCATCCTCTCCTTAAGCTACCTG
GGCCGGCATACCACTCAGGCCGCTGCCCTGCTCCTGGCAGGAGGGGCCATCTTGGCTCTC
ACCTTTGTGCCCTTGGACTTGCAGACCGTGAGGACAGTATTGGCTGTGTTTGGGAAGGGA
TGCCTATCCAGCTCCTTCAGCTGCCTCTTCCTCTACACAAGTGAATTATACCCCACAGTC
ATCAGGCAAACAGGTATGGGCGTAAGTAACCTGTGGACCCGCGTGGGAAGCATGGTGTCC
CCGCTGGTGAAAATCACGGGTGAGGTACAGCCCTTCATCCCCAATATCATCTACGGGATC
ACCGCCCTCCTCGGGGGCAGTGCTGCCCTCTTCCTGCCTGAGACCCTGAATCAGCCCTTG
CCAGAGACTATCGAAGACCTGGAAAACTGGTCCCTGCGGGCAAAGAAGCCAAAGCAGGAG
CCAGAGGTGGAAAAGGCCTCCCAGAGGATCCCTCTACAGCCTCACGGACCAGGCCTGGGC
TCCAGCTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00083</identifier>
            <name>Sugar_tr</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>basolateral plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular exosome</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>inorganic anion exchanger activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>sodium-independent organic anion transmembrane transporter activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>anion transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to toxic substance</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>sodium-independent organic anion transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transmembrane transport</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </transporter>
  </transporters>
</drug>